
==== Front
Curr Neuropharmacol
Curr Neuropharmacol
CN
Current Neuropharmacology
1570-159X
1875-6190
Bentham Science Publishers

37550908
CN-22-524
10.2174/1570159X21666230807152051
Medicine, Neurology, Pharmacology, Neuroscience
Inflammation in Posttraumatic Stress Disorder: Dysregulation or Recalibration?
Patas Kostas 1
Baker Dewleen G. 23
Chrousos George P. 4
Agorastos Agorastos 35*
1 Department of Biopathology and Laboratory Medicine, Eginition University Hospital, Athens, Greece;
2 Department of Psychiatry, University of California, San Diego (UCSD), La Jolla, CA, USA;
3 VA Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, La Jolla, San Diego, CA, USA;
4 University Research Institute of Maternal and Child Health and Precision Medicine and UNESCO Chair on Adolescent Health Care, National and Kapodistrian University of Athens, Medical School, Aghia Sophia Children's Hospital, Athens, Greece;
5 Department of Psychiatry, Division of Neurosciences, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Central Macedonia, Greece
* Address correspondence to this author at the Department of Psychiatry, Division of Neurosciences, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; Tel: +30 694 386 2465; Fax: +30 2310 458 776; E-mail: aagorast@auth.gr
07 8 2023
2024
22 4 524542
02 11 2022
04 1 2023
06 1 2023
© 2024 The Author(s). Published by Bentham Science Publishers
2024
The Author(s)
https://creativecommons.org/licenses/by/4.0/ © 2024 The Author(s). Published by Bentham Science Publishers. This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode.
Despite ample experimental data indicating a role of inflammatory mediators in the behavioral and neurobiological manifestations elicited by exposure to physical and psychologic stressors, causative associations between systemic low-grade inflammation and central nervous system inflammatory processes in posttraumatic stress disorder (PTSD) patients remain largely conceptual. As in other stress-related disorders, pro-inflammatory activity may play an equivocal role in PTSD pathophysiology, one that renders indiscriminate employment of anti-inflammatory agents of questionable relevance. In fact, as several pieces of preclinical and clinical research convergingly suggest, timely and targeted potentiation rather than inhibition of inflammatory responses may actually be beneficial in patients who are characterized by suppressed microglia function in the face of systemic low-grade inflammation. The deleterious impact of chronic stress-associated inflammation on the systemic level may, thus, need to be held in context with the - often not readily apparent - adaptive payoffs of low-grade inflammation at the tissue level.

Keywords

Posttraumatic stress disorder (PTSD)
immune system
inflammation
neurobiology
microglia
anti-inflammatory agents
==== Body
pmc1 INTRODUCTION

Posttraumatic stress disorder (PTSD) is a chronic and debilitating condition that manifests in the aftermath of one or more profoundly traumatic or life-threatening experiences. Despite the pervasiveness of traumatic events in modern societies worldwide [1], only a substantial minority among the trauma-exposed (ranging from 0.5% to 14.5% across countries) goes on to develop frank PTSD [2]. This suggests that either a disproportionate effect of rather uncommon susceptibility factors or sporadic deficiencies in rather common resilience factors, or more likely a critical mix of both [3-5], might tip the balance on who proceeds to clinical disease.

Rapidly growing evidence indicates that aberrant activity of the immune system/inflammatory reaction may be causally implicated in the pathophysiology of PTSD [6-9], as well as in the association of the disorder with increased risk for somatic manifestations and comorbidities (i.e., cardiovascular disease [10] and metabolic syndrome [11]), accelerated biological aging [12] and premature mortality [13]. However, the inference that the immune-inflammatory reaction is dysregulated in stress-related disorders seems to often disregard the critical question of why an inflammatory response is mounted in these disorders in the first place. This question becomes especially pertinent in light of experimental evidence showing that peripheral cytokines can regulate host behavior to optimize the organism’s ability to respond to environmental threats even in the absence of infection [14]. Relatedly, aspects of the immune-inflammatory response, including cell-mediated immunity, are now implicated not only in stress vulnerability but also in stress resilience through both peripheral and central mechanisms of action [15-17]. Therefore, we hereby discuss and re-evaluate the potential role of immune and inflammatory modifications in not merely mediating vulnerability and high medical comorbidity, but also paving the way to adaptation and resilience to PTSD.

2 STRESS-ASSOCIATED INFLAMMATION CAN BE BOTH FUNCTIONAL AND DYSFUNCTIONAL

2.1 Physical Stress and the Inflammatory Response

The immune system consists of tissues, cell populations, and soluble factors that function to regulate tissue and whole-body homeostasis by means of sensing and responding to physiological and environmental perturbations [18]. A pivotal homeostasis-maintaining process in this context is inflammation – an adaptive response that is initiated by adverse stimuli and dysfunctional systemic, tissue, or cellular states, which are set off either as a result of or in anticipation of the loss of homeostasis [19].

The inflammatory response operates within a dynamic range depending on the nature and abundance of its inducers: while typical inflammation induced by infection and tissue damage lies at one end of the spectrum, graded inflammatory responses of lower magnitude are stretching to the other end [20]. These lower-grade, intermediate inflammatory states that display some but not all of the characteristics of proper inflammation (and are, thus, often termed “parainflammation”) are triggered in response to tissue stress or malfunction and are considered more common but less characterized than the full-fledged inflammatory responses elicited by infection or overt injury [20]. It is thus appreciated that parainflammation and inflammation comprise overlapping components of the continuum of the stress response and extend the adaptive competence of the organism by complementing the homeostatic regulation imparted by the endocrine and autonomic nervous systems [20-23]. How inflammatory signals are functionally embedded in the maintenance of homeostasis at the tissue level is, however, less clear [19].

In a general sense, parainflammation and inflammation are called into action when upstream, tissue-level homeostatic effectors are insufficient or have been overwhelmed in their effort to remove or sequester the source of a disturbance [19, 21]. To this end, a variety of inflammatory mediators, including cytokines, acute phase reactants, and chemokines, are initially produced during innate (i.e., non-antigen-specific) immune responses and mobilize other immune cells and responsive tissues. This mobilization is normally proportional to the intensity of the disturbance and lasts for as long as the host needs it to adapt to the new, aberrant conditions and re-establish homeostasis. If these conditions are transient, an equally transient inflammatory response will be actively resolved after it has succeeded in restoring tissue structure and function. Timely inhibition of pro-inflammatory pathways is mediated by intertwined immune, endocrine, and neural regulatory mechanisms that safeguard against undue tissue and cell damage [24, 25]. By contrast, if the aberrant conditions are prolonged (owing to the persistence of the initiating stimuli and/or faulty resolution associated with either an excessive or a subnormal inflammatory response [26]), then a different, chronic type of reaction shifts the organism to different internal set-points. Although the progression from transient to non-resolving inflammatory responses is often not clear-cut [26], the adaptive, physiological aspects of chronic (para)inflammation are gradually and eventually less evident, as opposed to the maladaptive, pathological aspects. It is however presumed that, while often not readily apparent, a physiological counterpart of chronic (para)inflammation is, by and large, present [20]. This may be largely achieved by the fact that inflammatory mediators act on the same cellular functions involved in tissue physiology and homeostasis [19].

2.2 Psychological Stress and the Inflammatory Response

Adverse psychological conditions represent no exception with regard to their potential to function as inducers of a wide range of immune responses, including a readily measurable pro-inflammatory state [23]. Indeed, both acute and chronic psychosocial stressors in humans have been reliably associated with low-grade systemic inflammatory responses, largely resembling parainflammation [27, 28]. Although these responses can be unequivocally conceptualized as inherent physical manifestations of vigilance mechanisms towards real, imminent, or perceived threats, sustained low-grade inflammation in response to severe life challenges and enduring psychosocial stressors, such as those described in PTSD and other stress-related disorders ([29-31], see also next section), is rarely interpreted as a dynamic process with inherently pleiotropic - both detrimental and beneficial - implications [23, 32]. Indeed, it is commonly acknowledged that chronic engagement of the endocrine and autonomic stress response systems can affect the homeostatic efficiency of peripheral inflammatory processes towards either chronic disinhibition or excessive inhibition, resulting in systemic inflammation- or immunosuppression-related medical conditions, respectively [33, 34]. This line of work certainly provided valuable insight into the contribution of maladaptive aspects of inflammation to the development of chronic disease, it has however, also bolstered a binary understanding of stress-induced (para)inflammation, wherein mounting of a response is rather uniformly detrimental and its attenuation should be purely beneficial [32, 35].

Similarly, increasing evidence from preclinical models of environmental and psychosocial stress indicates that stress-induced activation of resident microglia in the central nervous system (CNS) leads to mild or modest pro-inflammatory responses that are reminiscent of parainflammation rather than bona fide, pathogenic neuroinflammation [36-39]. Cellular and molecular signals associated with stress-induced CNS microdamage [40, 41] are proposed to trigger in this setting a “sterile” microglia response which contributes to a recalibration of behavior in favor of neurorepair, but may nevertheless be prone to premature suppression [42, 43] or low-grade chronicity [38, 41]. On this account, an essentially adaptive CNS response to stressful conditions may be inadequate from the outset or ultimately amount to an unfavorable net effect in some individuals.

3 SYSTEMIC INFLAMMATION AND CELLULAR IMMUNOSENESCENCE IN PTSD

3.1 Enhanced Innate Immune Responses and Peripheral Inflammation

A growing body of evidence demonstrates a link between PTSD and a heightened systemic inflammatory tone [30, 44]. In particular, meta-analytic research shows that the disorder is cross-sectionally associated with increased levels of the cytokines interleukin-6 (IL-6), IL-1β, tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFN-γ) [6, 45], as well as of the pro-inflammatory C-C motif chemokine ligands (CCL)3, CCL4 and CCL5 [46]. Consequently, elevation in the levels of the cytokine-responsive acute phase reactant C-reactive protein (CRP) has been observed in individuals suffering from PTSD [6, 47, 48]. Of note, although cytokine mobilization and low-grade acute phase responses are not specific to the diagnosis of PTSD, exposure to psychological trauma has been linked to such pro-inflammatory activity transdiagnostically [49].

Blood-based transcriptomics broadened the scope of immunological understanding in PTSD pathogenesis by showing enhanced expression of numerous genes associated with cytokine/innate immune responses and type I IFN signaling [50], as opposed to weakened expression of genes associated with anti-inflammatory activity [51]. Epigenetic approaches point also to an altered immune function as a result of reduced methylation of immune-related genes in association with increased PTSD symptom severity [52, 53], as well as modifications of leukocyte microRNA expression more permissive to inflammation in PTSD patients [54, 55].

Indirect corroboration of a pro-inflammatory state in the periphery comes also from studies suggesting a blunted immune regulation in PTSD. Regulatory T (Treg) cells are pivotal in establishing an immunological set-point and a decrease in their frequency or function may indicate enhanced effector immune responses. Accordingly, a lower proportion of Treg cells [54, 56] and a less suppressive Treg phenotype in PTSD [57] hint at a disruption of immune homeostasis that may be further facilitating systemic inflammation and possibly pathological autoimmunity. Indeed, patients suffering from PTSD are at an increased risk not only for cardiovascular disease [10, 58] and metabolic syndrome [11], but also for autoimmune disease [59, 60].

Of note, several prospective studies have examined whether inflammation precedes the development of PTSD or vice versa. For instance, high pre-trauma CRP [61] or elevated IL-6 immediately after exposure to trauma [62] predict an elevated risk for PTSD. Similarly, over-expression of genes enriched for functions of innate immunity and IFN signaling at baseline has been associated with increased PTSD risk following trauma exposure [50], and a high capacity of leukocytes to produce cytokines upon stimulation has been associated with increases in PTSD symptoms in response to post-trauma severe life events [63]. However, recent studies showed that lower rather than higher levels of TNF-α and IFN-γ in the acute post-traumatic period are associated with subsequent risk for PTSD development [64], partly in a sexually dimorphic manner [65], indicating that, even in prospective designs, disentangling cause and effect may be challenging. In fact, despite the prevalence of plausible pathophysiological links between inflammation and PTSD, current longitudinal research precludes definite conclusions on directionality and causality [66].

3.2 Accelerated Aging of Cell-mediated Immunity and the Emerging Positive Role of T Cell Enhancement

A small but growing literature indicates that crucial components of cell-mediated immunity may undergo premature senescence in PTSD patients. It is well-known that functional decline in the T cell and natural killer (NK) cell compartments coexists with parainflammation in aging and aging-related diseases [67-69]. Interestingly, a comparable phenotypic and molecular signature of accelerated immunosenescence is generally evident in stress-related disorders [70, 71], including PTSD [12, 13, 72-75]. Besides neuroendocrine disruption [22], prematurely senescent immune phenotypes could be also partly associated with chronic antigenic stimulation [76, 77], as patients suffering from PTSD, despite being characterized by enhanced innate immune responses, are also at an increased risk for severe infections [78, 79]. In fact, chronic inflammatory signaling, possibly interlinked with oxidative stress, may directly contribute in this setting to T cell and NK cell suppression, similar to what has been described in various non-psychiatric medical conditions [80-82]. Acute phase reactants, particularly CRP, also interfere with antigen presentation, suppress T cell receptor engagement, and inhibit the expansion of antigen-specific T cells [83, 84]. However, it is increasingly apparent that cellular immunosenescence and inflammation represent two sides of the same ambivalent immunological state, one that may engender both functional and dysfunctional modes of adaptation [68, 85].

Beyond their role in host defense, T cells play also a vital role in CNS homeostasis and brain reserve, as shown by a large number of pertinent animal studies, reviewed in [86-88]. As such, it is conceivable that premature T cell senescence in PTSD may deprive the CNS of neuroprotective immune responses during chronic stress and trauma exposure. Indeed, T cell trafficking to the CNS is implicated in homeostatic mechanisms of coping with psychological trauma in preclinical models, and, therefore, targeted augmentation of beneficial CNS-directed T cell responses may constitute a novel approach to enhance resilience to traumatic stress, mainly via salutary effects on hippocampal plasticity and neurotrophic balance [89-92]. Importantly, such potentiation of T cell immunity enhances CNS immunosurveillance in stressed animals and attenuates chronic stress-induced behavioral deficits, when procured both before stress exposure (in the form of either active immunization with CNS-derived peptides [89, 90] or by transient depletion of peripheral Treg cells [92, 93]), as well as after exposure to chronic stress (in the form of adoptive transfer of stress-conditioned lymph node cells to chronically stressed lymphopenic animals [91, 94]).

From this perspective, lower Treg proportions and blunted suppressive phenotype in PTSD (see previous section) could be seen as a compensatory moderation of Treg function towards pro-inflammatory T cell effector responses and thereby as an endogenous effort to retain optimal CNS immune surveillance. Indeed, lower Treg percentages are accompanied by higher IFN-γ-producing T helper 1 (Th1) cell percentages in PTSD patients, in part due to a downregulation of microRNAs regulating the expression of the typical Th1 cytokine IFN-γ [54, 95]. Interestingly, elegant preclinical studies demonstrate a central role of systemic IFN-γ signaling, as well as of Th1 polarization of CNS-specific T cells in maintaining immunosurveillance of the CNS in both health and disease [96-98].

Another line of experimental evidence suggests that stress resilience can be achieved through immunization not only with self-antigens but also with non-pathogenic foreign antigens or whole microbes. The environmental saprophyte Mycobacterium vaccae is a prime example of a highly immunomodulatory microorganism, which has been repeatedly shown to prevent or ameliorate PTSD-relevant behavioral phenotypes when administered in heat-killed preparations [99-102]. Although it is generally considered that the stress-protective effects of M. vaccae are mainly mediated by the induction of Treg cells and an overall anti-inflammatory milieu in animal models, it is likely that the host-microbe interaction leads to a balanced expansion of pro-inflammatory effector T cell populations as well. For instance, human whole blood stimulation with heat-killed M. vaccae induced not only an increased release of cytokines (i.e., IL-6, TNF-α, as well as the anti-inflammatory cytokine IL-10), but also the upregulation of various adhesion molecules on innate immune cells [103], including the β2 integrins CD11a/CD18 (which are important for monocyte migration [104]) and the costimulatory receptor CD58 (which plays a critical role in T and NK cell activation and proliferation [105]). Importantly, mycobacterial stimulation of human whole blood resulted in increased monocyte expression of pivotal receptors for antigen presentation to CD4+ T cells, i.e., the major histocompatibility (MHC) class II molecules HLA-DP, HLA-DQ, and HLA-DR, and the T cell costimulatory molecules CD80/ CD86 [103], suggesting that enhanced T cell activation and proliferative capacity is involved in the beneficial immunomodulatory and behavioral effects following immunization with M. vaccae.

3.3 Multiple Pathways Leading to Peripheral Inflammation in Traumatic Stress

Although numerous biological links between traumatic stress and inflammation have been proposed, the underlying mechanisms are still not completely understood. In general, both genetic components (e.g., immunogenetic architecture [106] and sex-specific immune reactivity [107, 108]), as well as environmental/epigenetic influences seem to variably contribute to the inflammatory alterations observed in PTSD patients [7, 9]. Moreover, the timing of the environmental influences (i.e., pre- or post-trauma) provides an extra layer of intricacy. For instance, early-life adversities, i.e., parental separation, childhood maltreatment, and lower socioeconomic status, play a sizeable role in amplifying immune responses to stressors later in life [109, 110], while at the same time, inflammation can be fostered to some extent by altered lifestyle-related parameters, i.e., poor health behaviors, following trauma exposure [111, 112]. As discussed in the following sections, assembling known immunobiological information into converging pathophysiological pathways may not be a straightforward task, especially if certain pathway components concurrently allow for homeostatic adaptation.

3.4 Neuroendocrine Perturbations in PTSD

It is widely acknowledged that immune dysfunction can manifest as a consequence of stress-induced disruption of the hypothalamic-pituitary-adrenal (HPA) axis and the autonomic nervous system (ANS) [22, 33]. This is part of a complex, two-way interaction between the central and peripheral limbs of the stress system and the immune system [113-115], which gained particular interest in the pathophysiology of PTSD [116, 117].

On the one hand, post-traumatic ANS imbalance with increased sympathetic and reduced vagal activity [118] may directly augment pro-inflammatory responses [117, 119]. Stress mobilizes pro-inflammatory cytokines in the peripheral circulation [120], in part by activating the transcription factor Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) in mononuclear leukocytes following adrenergic stimulation [121]. Cytokines, however, unfold systemic effects beyond the orchestration of the host immune response and stimulate the secretion of glucocorticoids (GCs), which, although initially reinforce the innate immune system, are subsequently involved in the regulation and, eventually, termination of the inflammatory response [114, 122]. It is, thus, possible that suppressed ability of GCs to regulate inflammation due to low basal GC tone, may lead to untimely disinhibition of cytokine release in PTSD patients, or a subset thereof [123], thereby adding PTSD to a long list of inflammatory states associated with decreased HPA axis activity after major or prolonged stress [124]. Differential GC sensitivity among different immune cell subpopulations and altered GC-mediated transcriptional and post-transcriptional control of immune-related gene expression constitute downstream pathways through which post-traumatic HPA axis dysregulation may facilitate a pro-inflammatory state [116, 117].

At the same time, higher sensitivity of T cell, but not monocyte, proliferation to dexamethasone before military deployment has been associated with increased risk for elevated PTSD symptoms at 6 months post-deployment [125], suggesting that T cell activation deficits associated with increased regulation by GCs pre-exist in some PTSD patients. Lower basal GC signaling after PTSD development in these patients may, thus, in part stimulate T cell activation in a compensatory manner, leading to higher production of T cell-derived cytokines, such as IFN-γ. Indeed, GCs impair the trafficking of stress-protective leukocytes to the CNS, and systemic neutralization of GC signaling both amplified Th1 trafficking into the cerebrospinal fluid (CSF) and mitigated PTSD-like behavioral deficits [92]. In particular, increased GC signaling diminishes Th1 differentiation via both T cell-extrinsic and -intrinsic mechanisms [126, 127], suggesting that lower systemic GC tone in PTSD patients may serve Th1 homeostasis and, thus, immune surveillance of the stressed CNS. Nevertheless, under certain conditions, this may also facilitate the manifestation of inflammatory and autoimmune diseases [128].

3.5 Immune Genes Associated with PTSD

In addition to endocrine perturbations, genetic variants may also regulate certain aspects of immune reactivity in PTSD. For instance, single-nucleotide polymorphisms within inflammation-related genes (e.g., the CRP gene) may interact with PTSD to increase systemic inflammation and lead to heightened PTSD symptoms [48, 129]. Interestingly, the genetic association between CRP and PTSD is not unidirectional and appears to be at least in part accounted for by socioeconomic status [130]. Furthermore, genome-wide association data suggest immunogenetic loci, including HLA alleles, to be associated with PTSD [131-133], as well as with intergenerational trauma [134]. Epigenetic variation in the HLA and other genomic regions associated with immunity and inflammation, i.e., aryl hydrocarbon receptor repressor, IL-17 signaling, and the complement system, is likewise linked to PTSD risk [135-139]. HLA genes are highly polymorphic and varying combinations of different polymorphisms result in the expression of cell surface proteins with functionally distinct antigen presentation capacities. This leads to an individualized regulation of immune responses that impacts T cell activation, inflammation, as well as susceptibility or resilience to immune-mediated diseases [140]. Therefore, genetic and epigenetic variation in the HLA region may reciprocally shape these immunological domains in PTSD patients as well [106].

Intriguingly, in addition to their conventional role in the immune system, preclinical evidence shows that MHC class I molecules and their receptors are also expressed in the CNS, mediating important functions in neurodevelopment, neuronal plasticity, and stress reactivity [141, 142], suggesting that variation in the HLA class I region in PTSD patients may directly contribute to disease susceptibility or resilience. Similarly, mice lacking MHC class II genes, thus, notably deficient in CD4+ T cells, exhibit several behavioral abnormalities, along with suspension of microglia maturation [143]. Of note, microglia constitute the main antigen-presenting cell type in the mature CNS and their level of MHCII expression is linked to the CNS inflammatory response shaping pathology in common neurodegenerative diseases [144]. Certain subsets of MHCII-expressing microglia may nevertheless be able to drive antigen-specific neuroprotection [145, 146], once more indicating that the functional importance and directionality of the observed immunogenetic diversity in PTSD is largely unknown.

4 PTSD-ASSOCIATED INFLAMMATION IN THE CNS: TOO MUCH OR TOO LITTLE?

4.1 Animal Models and Translational Implications

Sensing of peripheral inflammatory activity by the CNS is believed to be enabled in PTSD by means of several communication pathways leading to perturbations in neurotransmitter metabolism, neural plasticity, cellular reduction-oxidation, microglia-driven neuroinflammation and excitotoxicity [7, 117, 147-150]. These pathways include active transport of peripheral cytokines across the blood-brain barrier (BBB), passive diffusion through leaky regions of the BBB, transmission of peripheral inflammatory signals by virtue of diverse neuroimmune receptors on afferent nerve fibers, and trafficking of mononuclear leukocytes to the CNS in response to chemoattractant signals originating from activated microglia and astrocytes [7, 117, 151].

However, it should be noted that a considerable part of the experimental work describing these pathways is based on the employment of exogenous inflammatory stimuli in otherwise non-stressed animals [152, 153], a model which may adequately recapitulate behavioral and neurobiological aspects of infection or cytokine therapy-induced inflammation in humans, but provides limited construct validity with regard to the pathogenesis of chronic stress-related disease [154]. Importantly, such an exogenous model largely precludes the delineation of potentially preventive or corrective functions of endogenous inflammation in response to the loss of proper neuroendocrine homeostasis elicited by chronic stress [22]. The latter becomes particularly relevant in view of the counterintuitive outcomes – i.e., no overall therapeutic effect or even worsening of psychiatric symptomatology – observed in patients with chronic stress-related disorders following anti-cytokine [155-157], nonsteroidal anti-inflammatory drug [158] or low-dose aspirin interventions [159, 160].

A more comprehensive view of PTSD-like behavioral and neurobiological phenotypes may be provided by animal studies employing more ecologically valid environmental stressors [161]. Neuroendocrine responses to such psychological stressors regulate both positively and negatively the production of inflammatory responses within CNS regions, such as the hypothalamus, the hippocampus, and the frontal cortex [162]. In particular, while central catecholamines stimulate the release of IL-1β from microglia through the activation of β2-adrenergic receptors, the stress-induced surge of GCs inhibits the production of CNS cytokines via both suppression of noradrenergic locus caeruleus neurons and inhibition of the NF-κB signaling pathway [162]. Animal findings further show that several pro-inflammatory pathways, most prominently the IL-1β signaling pathway, are activated within the CNS in response to both acute and chronic stressors and mediate disruption of hippocampal neurogenesis [163-165], suggesting that PTSD-associated inflammation may act as a negative regulator of neural plasticity and functional connectivity in humans [166]. Of note, the developmental timing of first trauma exposure may add an extra layer of complexity to the relation between neuroinflammation and disease pathogenesis, as data from animal studies show that early life adversity can inhibit homeostatic neuroinflammatory responses during early development, thereby leading to a sensitized immune response and heightened CNS inflammation later in life [167, 168].

Yet, peripherally induced inflammation in adult animals not only reverses stress-induced behavioral changes but also induces dramatic increases in neurogenesis, as well as recovery of hippocampal microglial proliferation following exposure to chronic unpredictable stress [42, 169], indicating a dynamic, context-dependent role of systemic inflammation in stress-related disorders. In fact, the exact effects of short-term vs. repeated stress exposure on microglia status, neurogenesis, and associated behavior can be diametrically opposed, that is, an initial period of microglial proliferation and activation may lead to subsequent microglial apoptosis and suppressed neurogenesis [42], with the latter being mediated, at least in part, by enhanced microglial checkpoint expression [170]. This suggests that experimental and therapeutic interventions in this setting should reckon with the CNS inflammatory status [171]. Indeed, aiming at either microglia inhibition or microglia stimulation in preclinical stress models seems to critically depend on whether these cells are in a state of activation or suppression, respectively [42, 43]. In a translational analogy, whereas acute experimental inflammation elicits clinical aspects of depression in healthy subjects [172], it induces mood improvement in severely depressed patients [173]. Moreover, recent preclinical data suggest that the amelioration of chronic stress-induced symptomatology by inflammatory stimulation of hippocampal microglia requires increased synthesis of brain-derived neurotrophic factors through activation of extracellular signal-regulated kinase 1/2 signaling [174].

Interestingly, while prior exposure to a stressor can potentiate microglia pro-inflammatory responses to a subsequent peripheral immune challenge [175], prior exposure to peripherally or intranasally administered innate immune stimuli can prevent rather than precipitate stress-induced behavioral abnormalities via microglia stimulation and concomitant increases of TNF-α, IL-6 and IL-1β in the hippocampus and frontal cortex [176-178]. Strikingly, single-event microglia stimulation (pro-inflammatory “vaccination”) in adolescent mice conferred long-lasting protection against heightened neuroinflammatory responses and behavioral abnormalities brought about by chronic stress in adulthood [179]. This prophylactic aspect of sterile inflammatory preconditioning further corroborates the notion that timely and controlled augmentation of inflammation may bear tolerance-inducing clinical benefits in stress-related disorders.

4.2 In vivo and Postmortem Human Observations

Similarly to peripheral inflammation, microglia activation in humans is not associated with a specific psychiatric diagnosis. Chronic psychosocial stress is instead hypothesized to be a common denominator across diagnoses or patient subgroups [180]. Interestingly, clinical and postmortem human brain data suggest that a PTSD diagnosis can be associated with both amplified and subnormal CNS inflammatory responses (Table 1). For instance, CSF IL-6 used as a surrogate marker of CNS inflammation showed no consistent alterations or covariation with peripheral IL-6 in PTSD patients [181-183], suggesting that peripheral cytokine signals may not readily or necessarily propagate in the CSF in some patients under unchallenged conditions. By contrast, an immediate and sustained increase of the pro-inflammatory IL-1β, as opposed to a delayed increase of the anti-inflammatory IL-10, in response to a deep pain stimulus was observed in the CSF of combat veterans with PTSD, indicating increased pain-induced neuroinflammatory sensitization [184].

What is further remarkable is that studies exploring parenchymal indications of neuroinflammation identify regionally diminished transcriptional signatures in PTSD, such as decreased IL1A gene expression in the dorsolateral prefrontal cortex (dlPFC) [185] and decreased expression of gene sets associated with immune-related pathways and microglia activity in both PFC and amygdala brain regions [186, 187]. Aberrant activity in cortico-amygdala neural circuits has been identified in both PTSD-relevant animal models and individuals with PTSD [188], and recent transcriptomic studies provide compelling evidence of strong microglia enrichments among genes with downregulated expression in these circuits in patients with PTSD relative to neurotypical individuals [187, 189]. Interestingly, co-expression network analyses indicate that while immune-related networks enriched for microglia-specific transcripts are indeed downregulated in the ventromedial PFC, other immune-related networks (e.g., enriched for TNF and interleukin genes) are largely upregulated in the dlPFC [190], suggesting subregional specificity of neuroimmune suppression in PTSD.

Along the same line, recent data from in vivo [11C]PBR28 positron emission tomography (PET) brain imaging of the 18-kDa translocator protein (TSPO), a biomarker of microglia activity in humans [191], demonstrate lower rather than higher TSPO availability in prefrontal-limbic regions in PTSD patients [186]. An additional layer of confirmation is provided by a PET study showing significantly higher availability of metabotropic glutamate receptor 5 (mGluR5) in the PFC and ventral striatum of PTSD patients, a finding that was corroborated by upregulation of the expression of SH3 And Multiple Ankyrin Repeat Domains 1 (SHANK1), which anchors mGluR5 to the cell surface [192]. Although this study did not report on indices of neuroinflammation, previous work has shown that mGluR5 activation inhibits microglia activation and has a suppressive effect on microglia-associated inflammation [193]. Apart from reduced microglia cell numbers and function, another PET study showed lower [11C]SL25.1188 availability in corticolimbic regions in PTSD, suggesting a loss of astrocytes as well [194]. Of note, astrocyte and microglia activation are commonly concurrent in the context of CNS inflammation [195] and astrocytes may be causally linked to PTSD pathogenesis [196].

Strikingly, lower TSPO availability - alluding to compromised microglial function - was associated with both higher blood CRP levels and greater PTSD severity [186]. As long as peripheral CRP contributes to central inflammation in PTSD [197], an inverse association of heightened systemic inflammatory activity with suppressed CNS inflammatory activity is perhaps reminiscent of the premise that chronic (para)inflammation has a physiological counterpart corresponding to tissue stress or malfunction [20, 21]. Given the prevalence of inflammation-targeting approaches in psychiatry and recent failures of both cytokine-specific and blanket anti-inflammatory interventions to separate from placebo in chronic stress-related disorders [156-160], such a re-interpretation may warrant further experimental and prospective investigation.

5 RE-INTERPRETATIONS AND CLINICAL IMPLICATIONS

The findings reviewed above reveal that the distinction of adaptive vs. dysregulated inflammatory responses in PTSD – and possibly other stress-related disorders – is not always readily drawn. According to converging evidence from several experimental and observational studies, it may be argued that some PTSD patients are characterized by systemic parainflammation in the face of microglia-associated neuroinflammatory suppression. Preclinical and clinical data further suggest that both anti-inflammatory and pro-inflammatory approaches may be therapeutically pertinent, depending on the contextual dynamics of stress-associated inflammation within the CNS rather than the incremental shift to a higher inflammatory set-point in the periphery (Fig. 1).

Maintenance of bodily tissue integrity and function depends on graded inflammatory and physiological self-reactive responses which are contingent upon the degree of tissue stress or malfunction that is being experienced [20, 198, 199]. This seems to extend to immune activation that is evoked by perturbations of CNS homeostasis [86, 200, 201]. What largely differentiates advantageous from disadvantageous immune activity is the intensity, timing, and context of its elicitation. In fact, neuroimmune responses to psychological stress may be better conceptualized on the basis of parainflammation (i.e., low-grade inflammatory responses to homeostatic threats) rather than on the basis of established concepts of neuroinflammation-driven pathology, as seen in CNS disease, injury or infection [39]. On this account, not every detectable aspect of immune and inflammatory alteration is expected to be of pathophysiological or therapeutic relevance to PTSD.

Notably, inflammation has neuroprotective properties widely described in the general field of neuroimmunology [37, 202, 203]. Elevations in circulating and topical cytokines, microglia activation, and recruitment of peripheral leukocytes into areas of the CNS are not necessarily undesirable [36]. In this regard, the magnitude of neural tissue malfunction can determine the magnitude of reciprocal immune-to-neural communication, whereby timely bouts of inflammation and controlled recruitment of systemic immune cells to the CNS may actually pave the way for neuro repair processes [204, 205]. A notable example of how peripheral and central inflammation may exert neuroprotection is the increased production and release of neurotrophic factors by mononuclear leukocytes [206, 207] and/resident microglia [174], a feature of immune activation with potential therapeutic relevance to CNS disorders [203, 208]. Fig. (2) summarizes possible mechanisms of immune stimulation leading to enhanced stress resilience.

Along with this notion, a dual role of low-grade IL-6 and CRP elevations in stress-related disorders is being gradually recognized [32, 209, 210]. This is conceptually important as both biomarkers have been extensively employed in many disease contexts to infer an underlying state of pathogenic inflammation rather than homeostasis-restoring inflammation. Of note, IL-6 is a prototypical cytokine with demonstrated functional pleiotropy and context-dependent pro- as well as anti-inflammatory properties [211-213], which, among others, connects peripheral regulatory processes with the CNS [214, 215]. Perhaps unsurprisingly, PTSD symptom severity has been associated with both higher [45] and lower levels [216, 217] of peripheral IL-6. A global blockade of IL-6 signaling would thus conceivably be expected to have heterogeneous, i.e. both on- and off-target effects, especially if patients are not stratified to have higher or lower levels of the target biomarker.

Indeed, a recent clinical study in patients undergoing allogeneic hematopoietic stem cell transplantation showed that global blockade of IL-6 receptors (i.e., both membrane-bound and soluble) by the monoclonal antibody tocilizumab was associated with worsening of depressive symptomatology [157], presumably due to indiscriminate blockade of IL-6 signaling in the periphery, increased BBB permeability of tocilizumab under conditions of significant peripheral inflammation and unrestricted activity of unbound IL-6 across the BBB [157, 218]. A similar note of caution is raised by recent safety signals about a potential link spontaneous depression and suicidal behavior with the use of specific monoclonal antibodies inhibiting the IL-17 receptor [219] or lymphocyte migration across the BBB [220], suggesting that abrupt reductions in systemic inflammatory signaling or CNS-directed immune reactivity may trigger adverse psychiatric effects in susceptible individuals [221].

Of direct relevance to the timing and efficacy of immune interventions in PTSD patients, recent prospective data suggest that an inflammatory response immediately after trauma exposure (as assessed by levels of TNF-α and IFN-γ) may mediate resilience rather than susceptibility to the disorder [64]. In view of the often opposing actions of both studied cytokines within the CNS [222, 223], the results of this study are setting the stage for further research on potentially adaptive aspects of acute peritraumatic inflammation. Indeed, follow-up work indicates that lower peritraumatic pro-inflammatory activity is prospectively associated with increased risk for nonremitting PTSD in women, while higher peritraumatic pro-inflammatory activity may confer PTSD resilience in men [65]. Preliminary prospective evidence likewise suggests that the pro-inflammatory C-X3-C motif chemokine ligand 1 (CX3CL1) is a PTSD resilience marker in US military service members [224]. Congruently, mice lacking CX3CL1 display cognitive dysfunction as a result of impaired synaptic plasticity and neurogenesis, while treatment with soluble CX3CL1 is able to, at least in part, restore these deficits [225]. If corroborated by further prospective and back-translational studies, a “paradigm shift” could be therefore reinforced whereby an initially deficient rather than excessive inflammatory response may drive in some cases the development of chronic PTSD [226]. Such a scenario could be seen as less counterintuitive in light of immunological studies showing that non-resolving inflammation may emanate from an inflammatory response that begins subnormally [26], along with preclinical evidence of proactive exposure to sterile inflammatory stimuli conferring tolerance to stress-induced behavioral and neurobiological abnormalities [176-179].

Critically, however, specific targeting of key components of non-resolving signaling pathways that converge to maintain systemic parainflammation in PTSD will eventually be needed in the chronic post-trauma phase. As genetic factors and inflexible environmental demands can progressively antagonize or undermine the adaptive capacity of an inflammatory response, endogenous inflammatory stimulation directed to the CNS can be gradually rendered suboptimal and inevitably maladaptive, especially for somatic tissues [113, 115, 227]. It is thus expected that nuanced anti-inflammatory and other immune-modulating interventions will be needed to curtail the increased medical burden associated with PTSD [228-230].

CONCLUSION

Initiation of inflammatory responses by disruptions of cellular and tissue homeostasis is deeply embedded in our biology, likely owing to the evolutionary prominence of such disruptions as forerunners of potential infection [231-233]. By extension, adverse psychosocial conditions, especially enduring or repeating ones leading to profound disruptions of neuroendocrine and immune cell homeostasis, could be seen as distinct environmental inducers of “preemptive” inflammation with both destructive (i.e., defense of the host) and restorative (i.e., defense of tissue homeostasis) capacities. Indeed, we now know that many inflammatory mediators can also operate as expanded homeostatic signals when a regulated variable deviates beyond the homeostatic range [19]. This may be an often overlooked and thus underexplored physiological aspect of parainflammation in stress-related disorders, one that argues for a balanced appreciation of both the value and the cost of the inflammatory response – and, as such, for a pragmatic and more personalized therapeutic targeting of the process.

ACKNOWLEDGEMENTS

Declared none.

LIST OF ABBREVIATIONS

ANS Autonomic Nervous System

CNS Central Nervous System

CRP C-reactive Protein

CSF Cerebrospinal Fluid

GCs Glucocorticoids

HPA Hypothalamic-pituitary-adrenal

IFN-γ Interferon-gamma

IL-6 Interleukin-6

NK Natural killer

PET Positron Emission Tomography

PTSD Posttraumatic Stress Disorder

TNF-α Tumor Necrosis Factor-alpha

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

None.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

Fig. (1) Proposed model represents the dynamic alterations in systemic inflammation and microglia activation status in PTSD based on the type of response in the periphery (A) and within the CNS (B). Non-resolving, low-grade inflammation in the chronic post-trauma phase may be associated with either an excessive or a subnormal inflammatory response in the acute post-trauma phase in both compartments. However, an excessive or subnormal CNS inflammatory response in the acute phase may also pave the way to a premature suppression of microglia activity. Accordingly, both anti-inflammatory approaches (acutely and subacutely post-trauma) and pro-inflammatory approaches (in the form of either pre-trauma immunization or post-trauma boosters) may be therapeutically pertinent, depending on whether the microglia compartment is in a state of overactivation or suppression, respectively.

Fig. (2) Potential therapeutic and/or prophylactic immunostimulatory approaches leading to enhanced stress resilience. References are provided in the text. Abbreviations: LPS: lipopolysaccharide; CNS: central nervous system; Treg: regulatory T cells; GC: glucocorticoid.

Table 1 CSF and CNS parenchymal inflammatory indices in PTSD.

Study Type	References	Sample Size	Methods	Highlights	Limitations	
In vivo (serial CSF and plasma)	Baker et al., 2001 [181]	PTSD: 11
Controls: 8	ELISA	• ↑ CSF IL-6 in PTSD
• ↔ plasma IL-6
• Negative correlation between CSF and plasma IL-6 in PTSD	• Sample size
• Only males	
In vivo (CSF) after paroxetine treatment	Bonne et al., 2011 [182]	PTSD: 16
Controls: 11	ELISA	• ↔ CSF IL-6 pretreatment
• ↔ CSF IL-6 posttreatment	• Sample size
• No peripheral measurements	
In vivo (diurnal CSF and plasma)	Agorastos et al., 2019 [183]	PTSD: 12
Combat controls: 12
Non-combat: 11	ELISA	• ↔ diurnal CSF IL-6
• ↔ diurnal plasma IL-6
• Circadian blunting of plasma IL-6 in all combat-exposed participants	• Sample size
• Only males	
In vivo (CSF) after deep pain stimulus	Lerman et al., 2016 [184]	PTSD: 10
Controls: 11	ECL	• ↑ CSF IL-1β post-injection in PTSD
• Delayed ↑ CSF IL-10 post-injection in PTSD	• Sample size
• Only males
• No peripheral measurements	
Postmortem brain gene expression	Morrison et al., 2019 [185]	PTSD: 12
MDD: 25
Controls: 13	RT-qPCR	• ↓ dlPFC IL1A in PTSD
• ↔ dlPFC IL1A compared to MDD	• Most PTSD cases comorbid with MDD
• No peripheral measurements	
In vivo (PET)	Bhatt et al., 2020 [186]	PTSD: 23
Controls: 26	Brain PET and immuno-turbidimetry	• ↓ Prefrontal-limbic TSPO availability in PTSD
• Negative correlation between TSPO availability and plasma CRP in PTSD	• Single time-point peripheral measurements
• PTSD sample with low medical burden due to exclusion criteria for PET	
Postmortem brain gene expression	Bhatt et al., 2020 [186]	PTSD: 22
Controls: 22	RT-qPCR	• ↓ PFC TSPO in females with PTSD
• ↓ PFC TNFRSF14 and TSPOAP1 in females with PTSD	• Inherent differences in clinical characteristics between postmortem and PET samples	
Postmortem brain transcriptomics	Jaffe et al., 2022 [187]	PTSD: 107
MDD: 109
Controls: 109	RNA-Seq	• ↓ PFC and amygdala immune-related pathways in PTSD
• ↓ PFC and amygdala microglia in PTSD	• Potential under-representation of female donors	
Postmortem brain transcriptomics	Girgenti et al., 2021 [189]	PTSD: 52
MDD: 45
Controls: 46	RNA-Seq	• ↓ dACC microglia in PTSD
• ↓ OFC and female sgPFC UBA7 in PTSD	• Microglia quantified by gene expression deconvolution	
Postmortem brain transcriptomics	Logue et al., 2021 [190]	PTSD: 38
MDD: 32
Controls: 24	RNA-Seq	• ↓ vmPFC microglia-related network in PTSD
• ↑ dlPFC immune-related network in PTSD	• PTSD cases comorbid with MDD were also included	
In vivo (PET)	Gill et al., 2022 [194]	PTSD: 13
Controls: 17	Brain PET	• ↓ mPFC and ventral striatum astrocytes in PTSD	• Sample size
• Possibly confounded by medication	
In vivo (PET)	Deri et al., 2021 [232]	World Trade Center responders: 20	Brain PET	• Positive correlation between PFC-hippocampal TSPO availability and PTSD symptom severity	• Subsyndromal PTSD
• Lack of control group	
In vivo (PET)	Toczek et al., 2019 [233]	PTSD: 9
Controls: 7	Systemic and brain PET	• ↔ FDG signal in the aorta, spleen, bone marrow, or amygdala
• Positive correlation between the amygdala, bone marrow, and splenic FDG signal in all participants	• Sample size
• Possible selection bias (young subjects)	
Abbreviations: ↑ increased, ↔ not different, ↓ decreased compared to a healthy control group (unless otherwise specified); CSF: cerebrospinal fluid; PFC: prefrontal cortex; dlPFC: dorsolateral prefrontal cortex; dACC: dorsal anterior cingulate cortex; OFC: orbitofrontal cortex; sgPFC: subgenual prefrontal cortex; vmPFC: ventromedial prefrontal cortex; PET: positron emission tomography; TSPO: 18-kDa translocator protein; TNFRSF14: TNF Superfamily Member 14; TSPOAP1: TSPO Associated Protein 1; UBA7: Ubiquitin-Like Modifier-Activating Enzyme 7; FDG: [18F]fluorodeoxyglucose; ELISA: enzyme-linked immunosorbent assay; ECL: electrochemiluminescence; MDD: major depressive disorder; RT-qPCR: reverse transcription quantitative real-time PCR; RNA-Seq: RNA sequencing.
==== Refs
REFERENCES

1 Benjet C. Bromet E. Karam E.G. Kessler R.C. McLaughlin K.A. Ruscio A.M. Shahly V. Stein D.J. Petukhova M. Hill E. Alonso J. Atwoli L. Bunting B. Bruffaerts R. Caldas-de-Almeida J.M. de Girolamo G. Florescu S. Gureje O. Huang Y. Lepine J.P. Kawakami N. Kovess-Masfety V. Medina-Mora M.E. Navarro-Mateu F. Piazza M. Posada-Villa J. Scott K.M. Shalev A. Slade T. ten Have M. Torres Y. Viana M.C. Zarkov Z. Koenen K.C. The epidemiology of traumatic event exposure worldwide: Results from the World Mental Health Survey Consortium. Psychol. Med. 2016 46 2 327 343 10.1017/S0033291715001981 26511595
2 Koenen K.C. Ratanatharathorn A. Ng L. McLaughlin K.A. Bromet E.J. Stein D.J. Karam E.G. Meron Ruscio A. Benjet C. Scott K. Atwoli L. Petukhova M. Lim C.C.W. Aguilar-Gaxiola S. Al-Hamzawi A. Alonso J. Bunting B. Ciutan M. de Girolamo G. Degenhardt L. Gureje O. Haro J.M. Huang Y. Kawakami N. Lee S. Navarro-Mateu F. Pennell B.E. Piazza M. Sampson N. ten Have M. Torres Y. Viana M.C. Williams D. Xavier M. Kessler R.C. Posttraumatic stress disorder in the World Mental Health Surveys. Psychol. Med. 2017 47 13 2260 2274 10.1017/S0033291717000708 28385165
3 Murrough J.W. Russo S.J. The neurobiology of resilience: Complexity and hope. Biol. Psychiatry 2019 86 6 406 409 10.1016/j.biopsych.2019.07.016 31466560
4 Hodes G.E. Epperson C.N. Sex differences in vulnerability and resilience to stress across the life span. Biol. Psychiatry 2019 86 6 421 432 10.1016/j.biopsych.2019.04.028 31221426
5 Agorastos A. Pervanidou P. Chrousos G.P. Baker D.G. Developmental trajectories of early life stress and trauma: A narrative review on neurobiological aspects beyond stress system dysregulation. Front. Psychiatry 2019 10 118 10.3389/fpsyt.2019.00118 30914979
6 Peruzzolo T.L. Pinto J.V. Roza T.H. Shintani A.O. Anzolin A.P. Gnielka V. Kohmann A.M. Marin A.S. Lorenzon V.R. Brunoni A.R. Kapczinski F. Passos I.C. Inflammatory and oxidative stress markers in post-traumatic stress disorder: A systematic review and meta-analysis. Mol. Psychiatry 2022 27 8 3150 3163 10.1038/s41380-022-01564-0 35477973
7 Katrinli S. Oliveira N.C.S. Felger J.C. Michopoulos V. Smith A.K. The role of the immune system in posttraumatic stress disorder. Transl. Psychiatry 2022 12 1 313 10.1038/s41398-022-02094-7 35927237
8 Sun Y. Qu Y. Zhu J. The relationship between inflammation and post-traumatic stress disorder. Front. Psychiatry 2021 12 707543 10.3389/fpsyt.2021.707543 34456764
9 Núñez-Rios D.L. Martínez-Magaña J.J. Nagamatsu S.T. Andrade-Brito D.E. Forero D.A. Orozco-Castaño C.A. Montalvo-Ortiz J.L. Central and peripheral immune dysregulation in posttraumatic stress disorder: Convergent multi-omics evidence. Biomedicines 2022 10 5 1107 10.3390/biomedicines10051107 35625844
10 O’Donnell C.J. Schwartz Longacre L. Cohen B.E. Fayad Z.A. Gillespie C.F. Liberzon I. Pathak G.A. Polimanti R. Risbrough V. Ursano R.J. Vander Heide R.S. Yancy C.W. Vaccarino V. Sopko G. Stein M.B. Posttraumatic stress disorder and cardiovascular disease. JAMA Cardiol. 2021 6 10 1207 1216 10.1001/jamacardio.2021.2530 34259831
11 Mellon S.H. Gautam A. Hammamieh R. Jett M. Wolkowitz O.M. Metabolism, metabolomics, and inflammation in posttraumatic stress disorder. Biol. Psychiatry 2018 83 10 866 875 10.1016/j.biopsych.2018.02.007 29628193
12 Wolf E.J. Maniates H. Nugent N. Maihofer A.X. Armstrong D. Ratanatharathorn A. Ashley-Koch A.E. Garrett M. Kimbrel N.A. Lori A. Aiello A.E. Baker D.G. Beckham J.C. Boks M.P. Galea S. Geuze E. Hauser M.A. Kessler R.C. Koenen K.C. Miller M.W. Ressler K.J. Risbrough V. Rutten B.P.F. Stein M.B. Ursano R.J. Vermetten E. Vinkers C.H. Uddin M. Smith A.K. Nievergelt C.M. Logue M.W. Traumatic stress and accelerated DNA methylation age: A meta-analysis. Psychoneuroendocrinology 2018 92 123 134 10.1016/j.psyneuen.2017.12.007 29452766
13 Yang R. Wu G.W.Y. Verhoeven J.E. Gautam A. Reus V.I. Kang J.I. Flory J.D. Abu-Amara D. Hood L. Doyle F.J. III Yehuda R. Marmar C.R. Jett M. Hammamieh R. Mellon S.H. Wolkowitz O.M. A DNA methylation clock associated with age-related illnesses and mortality is accelerated in men with combat PTSD. Mol. Psychiatry 2021 26 9 4999 5009 10.1038/s41380-020-0755-z 32382136
14 Salvador A.F. de Lima K.A. Kipnis J. Neuromodulation by the immune system: A focus on cytokines. Nat. Rev. Immunol. 2021 21 8 526 541 10.1038/s41577-021-00508-z 33649606
15 Ménard C. Pfau M.L. Hodes G.E. Russo S.J. Immune and neuroendocrine mechanisms of stress vulnerability and resilience. Neuropsychopharmacology 2017 42 1 62 80 10.1038/npp.2016.90 27291462
16 Dantzer R. Cohen S. Russo S.J. Dinan T.G. Resilience and immunity. Brain Behav. Immun. 2018 74 28 42 10.1016/j.bbi.2018.08.010 30102966
17 Cathomas F. Murrough J.W. Nestler E.J. Han M.H. Russo S.J. Neurobiology of resilience: Interface between mind and body. Biol. Psychiatry 2019 86 6 410 420 10.1016/j.biopsych.2019.04.011 31178098
18 Rankin L.C. Artis D. Beyond Host Defense: Emerging functions of the immune system in regulating complex tissue physiology. Cell 2018 173 3 554 567 10.1016/j.cell.2018.03.013 29677509
19 Meizlish M.L. Franklin R.A. Zhou X. Medzhitov R. Tissue homeostasis and inflammation. Annu. Rev. Immunol. 2021 39 1 557 581 10.1146/annurev-immunol-061020-053734 33651964
20 Medzhitov R. Origin and physiological roles of inflammation. Nature 2008 454 7203 428 435 10.1038/nature07201 18650913
21 Chovatiya R. Medzhitov R. Stress, inflammation, and defense of homeostasis. Mol. Cell 2014 54 2 281 288 10.1016/j.molcel.2014.03.030 24766892
22 Agorastos A. Chrousos G.P. The neuroendocrinology of stress: The stress-related continuum of chronic disease development. Mol. Psychiatry 2022 27 1 502 513 10.1038/s41380-021-01224-9 34290370
23 Haykin H. Rolls A. The neuroimmune response during stress: A physiological perspective. Immunity 2021 54 9 1933 1947 10.1016/j.immuni.2021.08.023 34525336
24 Webster J.I. Tonelli L. Sternberg E.M. Neuroendocrine regulation of immunity. Annu. Rev. Immunol. 2002 20 1 125 163 10.1146/annurev.immunol.20.082401.104914 11861600
25 Padro C.J. Sanders V.M. Neuroendocrine regulation of inflammation. Semin. Immunol. 2014 26 5 357 368 10.1016/j.smim.2014.01.003 24486056
26 Nathan C. Ding A. Nonresolving inflammation. Cell 2010 140 6 871 882 10.1016/j.cell.2010.02.029 20303877
27 Rohleder N. Stimulation of systemic low-grade inflammation by psychosocial stress. Psychosom. Med. 2014 76 3 181 189 10.1097/PSY.0000000000000049 24608036
28 Marsland A.L. Walsh C. Lockwood K. John-Henderson N.A. The effects of acute psychological stress on circulating and stimulated inflammatory markers: A systematic review and meta-analysis. Brain Behav. Immun. 2017 64 208 219 10.1016/j.bbi.2017.01.011 28089638
29 Gold P.W. Licinio J. Pavlatou M.G. Pathological parainflammation and endoplasmic reticulum stress in depression: Potential translational targets through the CNS insulin, klotho and PPAR-γ systems. Mol. Psychiatry 2013 18 2 154 165 10.1038/mp.2012.167 23183489
30 Speer K. Upton D. Semple S. McKune A. Systemic low-grade inflammation in post-traumatic stress disorder: A systematic review. J. Inflamm. Res. 2018 11 111 121 10.2147/JIR.S155903 29606885
31 Osimo E.F. Baxter L.J. Lewis G. Jones P.B. Khandaker G.M. Prevalence of low-grade inflammation in depression: A systematic review and meta-analysis of CRP levels. Psychol. Med. 2019 49 12 1958 1970 10.1017/S0033291719001454 31258105
32 Del Giudice M. Gangestad S.W. Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters. Brain Behav. Immun. 2018 70 61 75 10.1016/j.bbi.2018.02.013 29499302
33 Glaser R. Kiecolt-Glaser J.K. Stress-induced immune dysfunction: Implications for health. Nat. Rev. Immunol. 2005 5 3 243 251 10.1038/nri1571 15738954
34 Dhabhar F.S. Enhancing versus suppressive effects of stress on immune function: Implications for immunoprotection and immunopathology. Neuroimmunomodulation 2009 16 5 300 317 10.1159/000216188 19571591
35 Rubinow K.B. Rubinow D.R. In immune defense: Redefining the role of the immune system in chronic disease. Dialogues Clin. Neurosci. 2017 19 1 19 26 10.31887/DCNS.2017.19.1/drubinow 28566944
36 Estes M.L. McAllister A.K. Alterations in immune cells and mediators in the brain: It’s not always neuroinflammation! Brain Pathol. 2014 24 6 623 630 10.1111/bpa.12198 25345893
37 DiSabato D.J. Quan N. Godbout J.P. Neuroinflammation: The devil is in the details. J. Neurochem. 2016 139 Suppl. 2 136 153 10.1111/jnc.13607 26990767
38 Wohleb E.S. Neuron–microglia interactions in mental health disorders: “For better, and for worse”. Front. Immunol. 2016 7 544 10.3389/fimmu.2016.00544 27965671
39 Woodburn S.C. Bollinger J.L. Wohleb E.S. The semantics of microglia activation: Neuroinflammation, homeostasis, and stress. J. Neuroinflammation 2021 18 1 258 10.1186/s12974-021-02309-6 34742308
40 Shulman L.M. Emotional traumatic brain injury. Cogn. Behav. Neurol. 2020 33 4 301 303 10.1097/WNN.0000000000000243 32947370
41 Wager-Smith K. Markou A. Depression: A repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition? Neurosci. Biobehav. Rev. 2011 35 3 742 764 10.1016/j.neubiorev.2010.09.010 20883718
42 Kreisel T. Frank M.G. Licht T. Reshef R. Ben-Menachem-Zidon O. Baratta M.V. Maier S.F. Yirmiya R. Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol. Psychiatry 2014 19 6 699 709 10.1038/mp.2013.155 24342992
43 Tong L. Gong Y. Wang P. Hu W. Wang J. Chen Z. Zhang W. Huang C. Microglia loss contributes to the development of major depression induced by different types of chronic stresses. Neurochem. Res. 2017 42 10 2698 2711 10.1007/s11064-017-2270-4 28434164
44 Hori H. Kim Y. Inflammation and post‐traumatic stress disorder. Psychiatry Clin. Neurosci. 2019 73 4 143 153 10.1111/pcn.12820 30653780
45 Passos I.C. Vasconcelos-Moreno M.P. Costa L.G. Kunz M. Brietzke E. Quevedo J. Salum G. Magalhães P.V. Kapczinski F. Kauer-Sant’Anna M. Inflammatory markers in post-traumatic stress disorder: A systematic review, meta-analysis, and meta-regression. Lancet Psychiatry 2015 2 11 1002 1012 10.1016/S2215-0366(15)00309-0 26544749
46 Pan X. Kaminga A.C. Wu Wen S. Liu A. Chemokines in post-traumatic stress disorder: A network meta-analysis. Brain Behav. Immun. 2021 92 115 126 10.1016/j.bbi.2020.11.033 33242653
47 Spitzer C. Barnow S. Völzke H. Wallaschofski H. John U. Freyberger H.J. Löwe B. Grabe H.J. Association of posttraumatic stress disorder with low-grade elevation of C-reactive protein: Evidence from the general population. J. Psychiatr. Res. 2010 44 1 15 21 10.1016/j.jpsychires.2009.06.002 19628221
48 Michopoulos V. Rothbaum A.O. Jovanovic T. Almli L.M. Bradley B. Rothbaum B.O. Gillespie C.F. Ressler K.J. Association of CRP genetic variation and CRP level with elevated PTSD symptoms and physiological responses in a civilian population with high levels of trauma. Am. J. Psychiatry 2015 172 4 353 362 10.1176/appi.ajp.2014.14020263 25827033
49 Tursich M. Neufeld R.W.J. Frewen P.A. Harricharan S. Kibler J.L. Rhind S.G. Lanius R.A. Association of trauma exposure with proinflammatory activity: A transdiagnostic meta-analysis. Transl. Psychiatry 2014 4 7 e413 10.1038/tp.2014.56 25050993
50 Breen M.S. Maihofer A.X. Glatt S.J. Tylee D.S. Chandler S.D. Tsuang M.T. Risbrough V.B. Baker D.G. O’Connor D.T. Nievergelt C.M. Woelk C.H. Gene networks specific for innate immunity define post-traumatic stress disorder. Mol. Psychiatry 2015 20 12 1538 1545 10.1038/mp.2015.9 25754082
51 Breen M.S. Tylee D.S. Maihofer A.X. Neylan T.C. Mehta D. Binder E.B. Chandler S.D. Hess J.L. Kremen W.S. Risbrough V.B. Woelk C.H. Baker D.G. Nievergelt C.M. Tsuang M.T. Buxbaum J.D. Glatt S.J. PTSD blood transcriptome mega-analysis: Shared inflammatory pathways across biological sex and modes of trauma. Neuropsychopharmacology 2018 43 3 469 481 10.1038/npp.2017.220 28925389
52 Uddin M. Aiello A.E. Wildman D.E. Koenen K.C. Pawelec G. de los Santos R. Goldmann E. Galea S. Epigenetic and immune function profiles associated with posttraumatic stress disorder. Proc. Natl. Acad. Sci. USA 2010 107 20 9470 9475 10.1073/pnas.0910794107 20439746
53 Katrinli S. Maihofer A.X. Wani A.H. Pfeiffer J.R. Ketema E. Ratanatharathorn A. Baker D.G. Boks M.P. Geuze E. Kessler R.C. Risbrough V.B. Rutten B.P.F. Stein M.B. Ursano R.J. Vermetten E. Logue M.W. Nievergelt C.M. Smith A.K. Uddin M. Epigenome-wide meta-analysis of PTSD symptom severity in three military cohorts implicates DNA methylation changes in genes involved in immune system and oxidative stress. Mol. Psychiatry 2022 27 3 1720 1728 10.1038/s41380-021-01398-2 34992238
54 Zhou J. Nagarkatti P. Zhong Y. Ginsberg J.P. Singh N.P. Zhang J. Nagarkatti M. Dysregulation in microRNA expression is associated with alterations in immune functions in combat veterans with post-traumatic stress disorder. PLoS One 2014 9 4 e94075 10.1371/journal.pone.0094075 24759737
55 Bam M. Yang X. Zumbrun E.E. Ginsberg J.P. Leyden Q. Zhang J. Nagarkatti P.S. Nagarkatti M. Decreased AGO2 and DCR1 in PBMCs from War Veterans with PTSD leads to diminished miRNA resulting in elevated inflammation. Transl. Psychiatry 2017 7 8 e1222 10.1038/tp.2017.185 28850112
56 Sommershof A. Aichinger H. Engler H. Adenauer H. Catani C. Boneberg E.M. Elbert T. Groettrup M. Kolassa I.T. Substantial reduction of naïve and regulatory T cells following traumatic stress. Brain Behav. Immun. 2009 23 8 1117 1124 10.1016/j.bbi.2009.07.003 19619638
57 Jergović M. Bendelja K. Vidović A. Savić A. Vojvoda V. Aberle N. Rabatić S. Jovanovic T. Sabioncello A. Patients with post-traumatic stress disorder exhibit an altered phenotype of regulatory T cells. Allergy Asthma Clin. Immunol. 2014 10 1 43 10.1186/1710-1492-10-43 25670936
58 Edmondson D. Kronish I.M. Shaffer J.A. Falzon L. Burg M.M. Posttraumatic stress disorder and risk for coronary heart disease: A meta-analytic review. Am. Heart J. 2013 166 5 806 814 10.1016/j.ahj.2013.07.031 24176435
59 O’Donovan A. Cohen B.E. Seal K.H. Bertenthal D. Margaretten M. Nishimi K. Neylan T.C. Elevated risk for autoimmune disorders in iraq and afghanistan veterans with posttraumatic stress disorder. Biol. Psychiatry 2015 77 4 365 374 10.1016/j.biopsych.2014.06.015 25104173
60 Song H. Fang F. Tomasson G. Arnberg F.K. Mataix-Cols D. Fernández de la Cruz L. Almqvist C. Fall K. Valdimarsdóttir U.A. Association of stress-related disorders with subsequent autoimmune disease. JAMA 2018 319 23 2388 2400 10.1001/jama.2018.7028 29922828
61 Eraly S.A. Nievergelt C.M. Maihofer A.X. Barkauskas D.A. Biswas N. Agorastos A. O’Connor D.T. Baker D.G. Assessment of plasma C-reactive protein as a biomarker of posttraumatic stress disorder risk. JAMA Psychiatry 2014 71 4 423 431 10.1001/jamapsychiatry.2013.4374 24576974
62 Pervanidou P. Kolaitis G. Charitaki S. Margeli A. Ferentinos S. Bakoula C. Lazaropoulou C. Papassotiriou I. Tsiantis J. Chrousos G.P. Elevated morning serum interleukin (IL)-6 or evening salivary cortisol concentrations predict posttraumatic stress disorder in children and adolescents six months after a motor vehicle accident. Psychoneuroendocrinology 2007 32 8-10 991 999 10.1016/j.psyneuen.2007.07.001 17825995
63 Smid G.E. van Zuiden M. Geuze E. Kavelaars A. Heijnen C.J. Vermetten E. Cytokine production as a putative biological mechanism underlying stress sensitization in high combat exposed soldiers. Psychoneuroendocrinology 2015 51 534 546 10.1016/j.psyneuen.2014.07.010 25106657
64 Michopoulos V. Beurel E. Gould F. Dhabhar F.S. Schultebraucks K. Galatzer-Levy I. Rothbaum B.O. Ressler K.J. Nemeroff C.B. Association of prospective risk for chronic PTSD symptoms with low TNFα and IFNγ concentrations in the immediate aftermath of trauma exposure. Am. J. Psychiatry 2020 177 1 58 65 10.1176/appi.ajp.2019.19010039 31352811
65 Lalonde C.S. Mekawi Y. Ethun K.F. Beurel E. Gould F. Dhabhar F.S. Schultebraucks K. Galatzer-Levy I. Maples-Keller J.L. Rothbaum B.O. Ressler K.J. Nemeroff C.B. Stevens J.S. Michopoulos V. Sex differences in peritraumatic inflammatory cytokines and steroid hormones contribute to prospective risk for nonremitting posttraumatic stress disorder. Chronic Stress 2021 5 24705470211032208 10.1177/24705470211032208 34595364
66 Sumner J.A. Nishimi K.M. Koenen K.C. Roberts A.L. Kubzansky L.D. Posttraumatic stress disorder and inflammation: untangling issues of bidirectionality. Biol. Psychiatry 2020 87 10 885 897 10.1016/j.biopsych.2019.11.005 31932029
67 Bektas A. Schurman S.H. Sen R. Ferrucci L. Human T cell immunosenescence and inflammation in aging. J. Leukoc. Biol. 2017 102 4 977 988 10.1189/jlb.3RI0716-335R 28733462
68 Fulop T. Larbi A. Dupuis G. Le Page A. Frost E.H. Cohen A.A. Witkowski J.M. Franceschi C. Immunosenescence and inflamm-aging as two sides of the same coin: Friends or foes? Front. Immunol. 2018 8 1960 10.3389/fimmu.2017.01960 29375577
69 Solana C. Tarazona R. Solana R. Immunosenescence of natural killer cells, inflammation, and Alzheimer’s Disease. Int. J. Alzheimers Dis. 2018 2018 1 9 10.1155/2018/3128758 30515321
70 de Punder K. Heim C. Wadhwa P.D. Entringer S. Stress and immunosenescence: The role of telomerase. Psychoneuroendocrinology 2019 101 87 100 10.1016/j.psyneuen.2018.10.019 30445409
71 Patas K. Willing A. Demiralay C. Engler J.B. Lupu A. Ramien C. Schäfer T. Gach C. Stumm L. Chan K. Vignali M. Arck P.C. Friese M.A. Pless O. Wiedemann K. Agorastos A. Gold S.M. T Cell Phenotype and T cell receptor repertoire in patients with major depressive disorder. Front. Immunol. 2018 9 291 10.3389/fimmu.2018.00291 29515587
72 Miller M.W. Sadeh N. Traumatic stress, oxidative stress and post-traumatic stress disorder: Neurodegeneration and the accelerated-aging hypothesis. Mol. Psychiatry 2014 19 11 1156 1162 10.1038/mp.2014.111 25245500
73 Bersani F.S. Wolkowitz O.M. Milush J.M. Sinclair E. Eppling L. Aschbacher K. Lindqvist D. Yehuda R. Flory J. Bierer L.M. Matokine I. Abu-Amara D. Reus V.I. Coy M. Hough C.M. Marmar C.R. Mellon S.H. A population of atypical CD56-CD16+ natural killer cells is expanded in PTSD and is associated with symptom severity. Brain Behav. Immun. 2016 56 264 270 10.1016/j.bbi.2016.03.021 27025668
74 Aiello A.E. Dowd J.B. Jayabalasingham B. Feinstein L. Uddin M. Simanek A.M. Cheng C.K. Galea S. Wildman D.E. Koenen K. Pawelec G. PTSD is associated with an increase in aged T cell phenotypes in adults living in Detroit. Psychoneuroendocrinology 2016 67 133 141 10.1016/j.psyneuen.2016.01.024 26894484
75 Xiong Y. Wang Z. Young M.R.I. Reduced expression of immune mediators by T-Cell subpopulations of combat-exposed veterans with post-traumatic stress disorder. Front. Psychiatry 2019 10 693 10.3389/fpsyt.2019.00693 31620037
76 Bellon M. Nicot C. Telomere dynamics in immune senescence and exhaustion triggered by chronic viral infection. Viruses 2017 9 10 289 10.3390/v9100289 28981470
77 Reed R.G. Stress and immunological aging. Curr. Opin. Behav. Sci. 2019 28 38 43 10.1016/j.cobeha.2019.01.012 31179376
78 Song H. Fall K. Fang F. Erlendsdóttir H. Lu D. Mataix-Cols D. Fernández de la Cruz L. D’Onofrio B.M. Lichtenstein P. Gottfreðsson M. Almqvist C. Valdimarsdóttir U.A. Stress related disorders and subsequent risk of life threatening infections: Population based sibling controlled cohort study. BMJ 2019 367 l5784 10.1136/bmj.l5784 31645334
79 Jiang T. Farkas D.K. Ahern T.P. Lash T.L. Sørensen H.T. Gradus J.L. Posttraumatic stress disorder and incident infections. Epidemiology 2019 30 6 911 917 10.1097/EDE.0000000000001071 31584893
80 Kanterman J. Sade-Feldman M. Baniyash M. New insights into chronic inflammation-induced immunosuppression. Semin. Cancer Biol. 2012 22 4 307 318 10.1016/j.semcancer.2012.02.008 22387003
81 Behl T. Upadhyay T. Singh S. Chigurupati S. Alsubayiel A.M. Mani V. Vargas-De-La-Cruz C. Uivarosan D. Bustea C. Sava C. Stoicescu M. Radu A.F. Bungau S.G. Polyphenols targeting MAPK mediated oxidative stress and inflammation in rheumatoid arthritis. Molecules 2021 26 21 6570 10.3390/molecules26216570 34770980
82 Bhattacharyya S. Saha J. Tumour, oxidative stress and Host T cell response: Cementing the dominance. Scand. J. Immunol. 2015 82 6 477 488 10.1111/sji.12350 26286126
83 Zhang R. Becnel L. Li M. Chen C. Yao Q. C-reactive protein impairs human CD14+ monocyte-derived dendritic cell differentiation, maturation and function. Eur. J. Immunol. 2006 36 11 2993 3006 10.1002/eji.200635207 17051617
84 Yoshida T. Ichikawa J. Giuroiu I. Laino A.S. Hao Y. Krogsgaard M. Vassallo M. Woods D.M. Stephen Hodi F. Weber J. C reactive protein impairs adaptive immunity in immune cells of patients with melanoma. J. Immunother. Cancer 2020 8 1 e000234 10.1136/jitc-2019-000234 32303612
85 Fulop T. Larbi A. Hirokawa K. Cohen A.A. Witkowski J.M. Immunosenescence is both functional/adaptive and dysfunctional/maladaptive. Semin. Immunopathol. 2020 42 5 521 536 10.1007/s00281-020-00818-9 32930852
86 Schwartz M. Kipnis J. Rivest S. Prat A. How do immune cells support and shape the brain in health, disease, and aging? J. Neurosci. 2013 33 45 17587 17596 10.1523/JNEUROSCI.3241-13.2013 24198349
87 Schwartz M. Shechter R. Protective autoimmunity functions by intracranial immunosurveillance to support the mind: The missing link between health and disease. Mol. Psychiatry 2010 15 4 342 354 10.1038/mp.2010.31 20332793
88 Filiano A.J. Gadani S.P. Kipnis J. How and why do T cells and their derived cytokines affect the injured and healthy brain? Nat. Rev. Neurosci. 2017 18 6 375 384 10.1038/nrn.2017.39 28446786
89 Lewitus G.M. Cohen H. Schwartz M. Reducing post-traumatic anxiety by immunization. Brain Behav. Immun. 2008 22 7 1108 1114 10.1016/j.bbi.2008.05.002 18562161
90 Lewitus G.M. Schwartz M. Behavioral immunization: Immunity to self-antigens contributes to psychological stress resilience. Mol. Psychiatry 2009 14 5 532 536 10.1038/mp.2008.103 18779818
91 Scheinert R.B. Haeri M.H. Lehmann M.L. Herkenham M. Therapeutic effects of stress-programmed lymphocytes transferred to chronically stressed mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2016 70 1 7 10.1016/j.pnpbp.2016.04.010 27109071
92 Kertser A. Baruch K. Deczkowska A. Weiner A. Croese T. Kenigsbuch M. Cooper I. Tsoory M. Ben-Hamo S. Amit I. Schwartz M. Corticosteroid signaling at the brain-immune interface impedes coping with severe psychological stress. Sci. Adv. 2019 5 5 eaav4111 10.1126/sciadv.aav4111 31149632
93 Cohen H. Ziv Y. Cardon M. Kaplan Z. Matar M.A. Gidron Y. Schwartz M. Kipnis J. Maladaptation to mental stress mitigated by the adaptive immune system via depletion of naturally occurring regulatory CD4+CD25+ cells. J. Neurobiol. 2006 66 6 552 563 10.1002/neu.20249 16555237
94 Brachman R.A. Lehmann M.L. Maric D. Herkenham M. Lymphocytes from chronically stressed mice confer antidepressant-like effects to naive mice. J. Neurosci. 2015 35 4 1530 1538 10.1523/JNEUROSCI.2278-14.2015 25632130
95 Bam M. Yang X. Zhou J. Ginsberg J.P. Leyden Q. Nagarkatti P.S. Nagarkatti M. Evidence for epigenetic regulation of pro-inflammatory cytokines, interleukin-12 and interferon gamma, in peripheral blood mononuclear cells from PTSD patients. J. Neuroimmune Pharmacol. 2016 11 1 168 181 10.1007/s11481-015-9643-8 26589234
96 Kipnis J. Yoles E. Mizrahi T. Ben-Nur A. Schwartz M. Myelin specific Th1 cells are necessary for post-traumatic protective auto-immunity. J. Neuroimmunol. 2002 130 1-2 78 85 10.1016/S0165-5728(02)00219-9 12225890
97 Kunis G. Baruch K. Rosenzweig N. Kertser A. Miller O. Berkutzki T. Schwartz M. IFN-γ-dependent activation of the brain’s choroid plexus for CNS immune surveillance and repair. Brain 2013 136 11 3427 3440 10.1093/brain/awt259 24088808
98 Fisher Y. Strominger I. Biton S. Nemirovsky A. Baron R. Monsonego A. Th1 polarization of T cells injected into the cerebrospinal fluid induces brain immunosurveillance. J. Immunol. 2014 192 1 92 102 10.4049/jimmunol.1301707 24307730
99 Reber S.O. Siebler P.H. Donner N.C. Morton J.T. Smith D.G. Kopelman J.M. Lowe K.R. Wheeler K.J. Fox J.H. Hassell J.E. Jr Greenwood B.N. Jansch C. Lechner A. Schmidt D. Uschold-Schmidt N. Füchsl A.M. Langgartner D. Walker F.R. Hale M.W. Lopez Perez G. Van Treuren W. González A. Halweg-Edwards A.L. Fleshner M. Raison C.L. Rook G.A. Peddada S.D. Knight R. Lowry C.A. Immunization with a heat-killed preparation of the environmental bacterium Mycobacterium vaccae promotes stress resilience in mice. Proc. Natl. Acad. Sci. USA 2016 113 22 E3130 E3139 10.1073/pnas.1600324113 27185913
100 Fox J.H. Hassell J.E. Jr Siebler P.H. Arnold M.R. Lamb A.K. Smith D.G. Day H.E.W. Smith T.M. Simmerman E.M. Outzen A.A. Holmes K.S. Brazell C.J. Lowry C.A. Preimmunization with a heat-killed preparation of Mycobacterium vaccae enhances fear extinction in the fear-potentiated startle paradigm. Brain Behav. Immun. 2017 66 70 84 10.1016/j.bbi.2017.08.014 28888667
101 Amoroso M. Böttcher A. Lowry C.A. Langgartner D. Reber S.O. Subcutaneous Mycobacterium vaccae promotes resilience in a mouse model of chronic psychosocial stress when administered prior to or during psychosocial stress. Brain Behav. Immun. 2020 87 309 317 10.1016/j.bbi.2019.12.018 31887415
102 Bowers S.J. Lambert S. He S. Lowry C.A. Fleshner M. Wright K.P. Jr Turek F.W. Vitaterna M.H. Immunization with a heat-killed bacterium, Mycobacterium vaccae NCTC 11659, prevents the development of cortical hyperarousal and a PTSD-like sleep phenotype after sleep disruption and acute stress in mice. Sleep 2021 44 6 zsaa271 10.1093/sleep/zsaa271 33283862
103 Bazzi S. Modjtahedi H. Mudan S. Akle C. Bahr G.M. Analysis of the immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model. Immunobiology 2015 220 12 1293 1304 10.1016/j.imbio.2015.07.015 26253276
104 Schittenhelm L. Hilkens C.M. Morrison V.L. β2 integrins as regulators of dendritic cell, monocyte, and macrophage function. Front. Immunol. 2017 8 1866 10.3389/fimmu.2017.01866 29326724
105 Zhang Y. Liu Q. Yang S. Liao Q. CD58 immunobiology at a glance. Front. Immunol. 2021 12 705260 10.3389/fimmu.2021.705260 34168659
106 Katrinli S. Smith A.K. Immune system regulation and role of the human leukocyte antigen in posttraumatic stress disorder. Neurobiol. Stress 2021 15 100366 10.1016/j.ynstr.2021.100366 34355049
107 Klein S.L. Flanagan K.L. Sex differences in immune responses. Nat. Rev. Immunol. 2016 16 10 626 638 10.1038/nri.2016.90 27546235
108 Fonkoue I.T. Michopoulos V. Park J. Sex differences in post-traumatic stress disorder risk: Autonomic control and inflammation. Clin. Auton. Res. 2020 30 5 409 421 10.1007/s10286-020-00729-7 33021709
109 Nusslock R. Miller G.E. Early-life adversity and physical and emotional health across the lifespan: A neuroimmune network hypothesis. Biol. Psychiatry 2016 80 1 23 32 10.1016/j.biopsych.2015.05.017 26166230
110 Danese A. J Lewis S. Psychoneuroimmunology of early-life stress: The hidden wounds of childhood trauma? Neuropsychopharmacology 2017 42 1 99 114 10.1038/npp.2016.198 27629365
111 Zen A.L. Whooley M.A. Zhao S. Cohen B.E. Post-traumatic stress disorder is associated with poor health behaviors: Findings from the Heart and Soul Study. Health Psychol. 2012 31 2 194 201 10.1037/a0025989 22023435
112 Dennis P.A. Weinberg J.B. Calhoun P.S. Watkins L.L. Sherwood A. Dennis M.F. Beckham J.C. An investigation of vago-regulatory and health-behavior accounts for increased inflammation in posttraumatic stress disorder. J. Psychosom. Res. 2016 83 33 39 10.1016/j.jpsychores.2016.02.008 27020074
113 Pace T.W.W. Heim C.M. A short review on the psychoneuroimmunology of posttraumatic stress disorder: From risk factors to medical comorbidities. Brain Behav. Immun. 2011 25 1 6 13 10.1016/j.bbi.2010.10.003 20934505
114 Cain D.W. Cidlowski J.A. Immune regulation by glucocorticoids. Nat. Rev. Immunol. 2017 17 4 233 247 10.1038/nri.2017.1 28192415
115 Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N. Engl. J. Med. 1995 332 20 1351 1363 10.1056/NEJM199505183322008 7715646
116 Daskalakis N.P. New translational perspectives for blood-based biomarkers of PTSD: From glucocorticoid to immune mediators of stress susceptibility. Exp. Neurol. 2016 284 Pt B 133 140 10.1016/j.expneurol.2016.07.024 27481726
117 Michopoulos V. Powers A. Gillespie C.F. Ressler K.J. Jovanovic T. Inflammation in fear- and anxiety-based disorders: PTSD, GAD, and beyond. Neuropsychopharmacology 2017 42 1 254 270 10.1038/npp.2016.146 27510423
118 Agorastos A. Boel J.A. Heppner P.S. Hager T. Moeller-Bertram T. Haji U. Motazedi A. Yanagi M.A. Baker D.G. Stiedl O. Diminished vagal activity and blunted diurnal variation of heart rate dynamics in posttraumatic stress disorder. Stress 2013 16 3 300 310 10.3109/10253890.2012.751369 23167763
119 Matteoli G. Boeckxstaens G.E. The vagal innervation of the gut and immune homeostasis. Gut 2013 62 8 1214 1222 10.1136/gutjnl-2012-302550 23023166
120 Steptoe A. Hamer M. Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: A review and meta-analysis. Brain Behav. Immun. 2007 21 7 901 912 10.1016/j.bbi.2007.03.011 17475444
121 Bierhaus A. Wolf J. Andrassy M. Rohleder N. Humpert P.M. Petrov D. Ferstl R. von Eynatten M. Wendt T. Rudofsky G. Joswig M. Morcos M. Schwaninger M. McEwen B. Kirschbaum C. Nawroth P.P. A mechanism converting psychosocial stress into mononuclear cell activation. Proc. Natl. Acad. Sci. USA 2003 100 4 1920 1925 10.1073/pnas.0438019100 12578963
122 Meduri G.U. Chrousos G.P. General Adaptation in Critical Illness: Glucocorticoid receptor-alpha master regulator of homeostatic corrections. Front. Endocrinol. 2020 11 161 10.3389/fendo.2020.00161 32390938
123 Meewisse M.L. Reitsma J.B. De Vries G.J. Gersons B.P.R. Olff M. Cortisol and post-traumatic stress disorder in adults. Br. J. Psychiatry 2007 191 5 387 392 10.1192/bjp.bp.106.024877 17978317
124 Chrousos G.P. Kaltsas G. Post-SARS sickness syndrome manifestations and endocrinopathy: How, why, and so what? Clin. Endocrinol. (Oxf.) 2005 63 4 363 365 10.1111/j.1365-2265.2005.02361.x 16181227
125 van Zuiden M. Heijnen C.J. Maas M. Amarouchi K. Vermetten E. Geuze E. Kavelaars A. Glucocorticoid sensitivity of leukocytes predicts PTSD, depressive and fatigue symptoms after military deployment: A prospective study. Psychoneuroendocrinology 2012 37 11 1822 1836 10.1016/j.psyneuen.2012.03.018 22503138
126 Elenkov I.J. Chrousos G.P. Stress Hormones, Th1/Th2 patterns, Pro/Anti-inflammatory cytokines and susceptibility to disease. Trends Endocrinol. Metab. 1999 10 9 359 368 10.1016/S1043-2760(99)00188-5 10511695
127 Capelle C.M. Chen A. Zeng N. Baron A. Grzyb K. Arns T. Skupin A. Ollert M. Hefeng F.Q. Stress hormone signalling inhibits Th1 polarization in a CD4 T‐cell‐intrinsic manner via mTORC1 and the circadian gene PER1. Immunology 2022 165 4 428 444 10.1111/imm.13448 35143696
128 Elenkov I.J. Iezzoni D.G. Daly A. Harris A.G. Chrousos G.P. Cytokine dysregulation, inflammation and well-being. Neuroimmunomodulation 2005 12 5 255 269 10.1159/000087104 16166805
129 Miller M.W. Maniates H. Wolf E.J. Logue M.W. Schichman S.A. Stone A. Milberg W. McGlinchey R. CRP polymorphisms and DNA methylation of the AIM2 gene influence associations between trauma exposure, PTSD, and C-reactive protein. Brain Behav. Immun. 2018 67 194 202 10.1016/j.bbi.2017.08.022 28867284
130 Muniz Carvalho C. Wendt F.R. Maihofer A.X. Stein D.J. Stein M.B. Sumner J.A. Hemmings S.M.J. Nievergelt C.M. Koenen K.C. Gelernter J. Belangero S.I. Polimanti R. Dissecting the genetic association of C-reactive protein with PTSD, traumatic events, and social support. Neuropsychopharmacology 2021 46 6 1071 1077 10.1038/s41386-020-0655-6 32179874
131 Stein M.B. Chen C.Y. Ursano R.J. Cai T. Gelernter J. Heeringa S.G. Jain S. Jensen K.P. Maihofer A.X. Mitchell C. Nievergelt C.M. Nock M.K. Neale B.M. Polimanti R. Ripke S. Sun X. Thomas M.L. Wang Q. Ware E.B. Borja S. Kessler R.C. Smoller J.W. Genome-wide Association Studies of Posttraumatic Stress Disorder in 2 Cohorts of US Army Soldiers. JAMA Psychiatry 2016 73 7 695 704 10.1001/jamapsychiatry.2016.0350 27167565
132 Katrinli S. Lori A. Kilaru V. Carter S. Powers A. Gillespie C.F. Wingo A.P. Michopoulos V. Jovanovic T. Ressler K.J. Smith A.K. Association of HLA locus alleles with posttraumatic stress disorder. Brain Behav. Immun. 2019 81 655 658 10.1016/j.bbi.2019.07.016 31310798
133 Nievergelt C.M. Maihofer A.X. Klengel T. Atkinson E.G. Chen C.Y. Choi K.W. Coleman J.R.I. Dalvie S. Duncan L.E. Gelernter J. Levey D.F. Logue M.W. Polimanti R. Provost A.C. Ratanatharathorn A. Stein M.B. Torres K. Aiello A.E. Almli L.M. Amstadter A.B. Andersen S.B. Andreassen O.A. Arbisi P.A. Ashley-Koch A.E. Austin S.B. Avdibegovic E. Babić D. Bækvad-Hansen M. Baker D.G. Beckham J.C. Bierut L.J. Bisson J.I. Boks M.P. Bolger E.A. Børglum A.D. Bradley B. Brashear M. Breen G. Bryant R.A. Bustamante A.C. Bybjerg-Grauholm J. Calabrese J.R. Caldas- de- Almeida, J.M.; Dale, A.M.; Daly, M.J.; Daskalakis, N.P.; Deckert, J.; Delahanty, D.L.; Dennis, M.F.; Disner, S.G.; Domschke, K.; Dzubur-Kulenovic, A.; Erbes, C.R.; Evans, A.; Farrer, L.A.; Feeny, N.C.; Flory, J.D.; Forbes, D.; Franz, C.E.; Galea, S.; Garrett, M.E.; Gelaye, B.; Geuze, E.; Gillespie, C.; Uka, A.G.; Gordon, S.D.; Guffanti, G.; Hammamieh, R.; Harnal, S.; Hauser, M.A.; Heath, A.C.; Hemmings, S.M.J.; Hougaard, D.M.; Jakovljevic, M.; Jett, M.; Johnson, E.O.; Jones, I.; Jovanovic, T.; Qin, X.J.; Junglen, A.G.; Karstoft, K.I.; Kaufman, M.L.; Kessler, R.C.; Khan, A.; Kimbrel, N.A.; King, A.P.; Koen, N.; Kranzler, H.R.; Kremen, W.S.; Lawford, B.R.; Lebois, L.A.M.; Lewis, C.E.; Linnstaedt, S.D.; Lori, A.; Lugonja, B.; Luykx, J.J.; Lyons, M.J.; Maples-Keller, J.; Marmar, C.; Martin, A.R.; Martin, N.G.; Maurer, D.; Mavissakalian, M.R.; McFarlane, A.; McGlinchey, R.E.; McLaughlin, K.A.; McLean, S.A.; McLeay, S.; Mehta, D.; Milberg, W.P.; Miller, M.W.; Morey, R.A.; Morris, C.P.; Mors, O.; Mortensen, P.B.; Neale, B.M.; Nelson, E.C.; Nordentoft, M.; Norman, S.B.; O’Donnell, M.; Orcutt, H.K.; Panizzon, M.S.; Peters, E.S.; Peterson, A.L.; Peverill, M.; Pietrzak, R.H.; Polusny, M.A.; Rice, J.P.; Ripke, S.; Risbrough, V.B.; Roberts, A.L.; Rothbaum, A.O.; Rothbaum, B.O.; Roy-Byrne, P.; Ruggiero, K.; Rung, A.; Rutten, B.P.F.; Saccone, N.L.; Sanchez, S.E.; Schijven, D.; Seedat, S.; Seligowski, A.V.; Seng, J.S.; Sheerin, C.M.; Silove, D.; Smith, A.K.; Smoller, J.W.; Sponheim, S.R.; Stein, D.J.; Stevens, J.S.; Sumner, J.A.; Teicher, M.H.; Thompson, W.K.; Trapido, E.; Uddin, M.; Ursano, R.J.; van den Heuvel, L.L.; Van Hooff, M.; Vermetten, E.; Vinkers, C.H.; Voisey, J.; Wang, Y.; Wang, Z.; Werge, T.; Williams, M.A.; Williamson, D.E.; Winternitz, S.; Wolf, C.; Wolf, E.J.; Wolff, J.D.; Yehuda, R.; Young, R.M.; Young, K.A.; Zhao, H.; Zoellner, L.A.; Liberzon, I.; Ressler, K.J.; Haas, M.; Koenen, K.C. International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci. Nat. Commun. 2019 10 1 4558 10.1038/s41467-019-12576-w 31594949
134 Daskalakis N.P. Xu C. Bader H.N. Chatzinakos C. Weber P. Makotkine I. Lehrner A. Bierer L.M. Binder E.B. Yehuda R. Intergenerational trauma is associated with expression alterations in glucocorticoid- and immune-related genes. Neuropsychopharmacology 2021 46 4 763 773 10.1038/s41386-020-00900-8 33173192
135 Snijders C. Maihofer A.X. Ratanatharathorn A. Baker D.G. Boks M.P. Geuze E. Jain S. Kessler R.C. Pishva E. Risbrough V.B. Stein M.B. Ursano R.J. Vermetten E. Vinkers C.H. Smith A.K. Uddin M. Rutten B.P.F. Nievergelt C.M. Longitudinal epigenome-wide association studies of three male military cohorts reveal multiple CpG sites associated with post-traumatic stress disorder. Clin. Epigenetics 2020 12 1 11 10.1186/s13148-019-0798-7 31931860
136 Smith A.K. Ratanatharathorn A. Maihofer A.X. Naviaux R.K. Aiello A.E. Amstadter A.B. Ashley-Koch A.E. Baker D.G. Beckham J.C. Boks M.P. Bromet E. Dennis M. Galea S. Garrett M.E. Geuze E. Guffanti G. Hauser M.A. Katrinli S. Kilaru V. Kessler R.C. Kimbrel N.A. Koenen K.C. Kuan P.F. Li K. Logue M.W. Lori A. Luft B.J. Miller M.W. Naviaux J.C. Nugent N.R. Qin X. Ressler K.J. Risbrough V.B. Rutten B.P.F. Stein M.B. Ursano R.J. Vermetten E. Vinkers C.H. Wang L. Youssef N.A. Marx C. Grant G. Stein M. Qin X-J. Jain S. McAllister T.W. Zafonte R. Lang A. Coimbra R. Andaluz N. Shutter L. George M.S. Brancu M. Calhoun P.S. Dedert E. Elbogen E.B. Fairbank J.A. Hurley R.A. Kilts J.D. Kirby A. Marx C.E. McDonald S.D. Moore S.D. Morey R.A. Naylor J.C. Rowland J.A. Swinkels C. Szabo S.T. Taber K.H. Tupler L.A. Van Voorhees E.E. Yoash-Gantz R.E. Basu A. Brick L.A. Dalvie S. Daskalakis N.P. Ensink J.B.M. Hemmings S.M.J. Herringa R. Ikiyo S. Koen N. Kuan P.F. Montalvo-Ortiz J. Nispeling D. Pfeiffer J. Qin X.J. Ressler K.J. Schijven D. Seedat S. Shinozaki G. Sumner J.A. Swart P. Tyrka A. Van Zuiden M. Wani A. Wolf E.J. Zannas A. Uddin M. Nievergelt C.M. Epigenome-wide meta-analysis of PTSD across 10 military and civilian cohorts identifies methylation changes in AHRR. Nat. Commun. 2020 11 1 5965 10.1038/s41467-020-19615-x 33235198
137 Katrinli S. Zheng Y. Gautam A. Hammamieh R. Yang R. Venkateswaran S. Kilaru V. Lori A. Hinrichs R. Powers A. Gillespie C.F. Wingo A.P. Michopoulos V. Jovanovic T. Wolf E.J. McGlinchey R.E. Milberg W.P. Miller M.W. Kugathasan S. Jett M. Logue M.W. Ressler K.J. Smith A.K. PTSD is associated with increased DNA methylation across regions of HLA-DPB1 and SPATC1L. Brain Behav. Immun. 2021 91 429 436 10.1016/j.bbi.2020.10.023 33152445
138 Rutten B.P.F. Vermetten E. Vinkers C.H. Ursini G. Daskalakis N.P. Pishva E. de Nijs L. Houtepen L.C. Eijssen L. Jaffe A.E. Kenis G. Viechtbauer W. van den Hove D. Schraut K.G. Lesch K-P. Kleinman J.E. Hyde T.M. Weinberger D.R. Schalkwyk L. Lunnon K. Mill J. Cohen H. Yehuda R. Baker D.G. Maihofer A.X. Nievergelt C.M. Geuze E. Boks M.P.M. Longitudinal analyses of the DNA methylome in deployed military servicemen identify susceptibility loci for post-traumatic stress disorder. Mol. Psychiatry 2018 23 5 1145 1156 10.1038/mp.2017.120 28630453
139 Logue M.W. Miller M.W. Wolf E.J. Huber B.R. Morrison F.G. Zhou Z. Zheng Y. Smith A.K. Daskalakis N.P. Ratanatharathorn A. Uddin M. Nievergelt C.M. Ashley-Koch A.E. Baker D.G. Beckham J.C. Garrett M.E. Boks M.P. Geuze E. Grant G.A. Hauser M.A. Kessler R.C. Kimbrel N.A. Maihofer A.X. Marx C.E. Qin X.J. Risbrough V.B. Rutten B.P.F. Stein M.B. Ursano R.J. Vermetten E. Vinkers C.H. Ware E.B. Stone A. Schichman S.A. McGlinchey R.E. Milberg W.P. Hayes J.P. Verfaellie M. An epigenome-wide association study of posttraumatic stress disorder in US veterans implicates several new DNA methylation loci. Clin. Epigenetics 2020 12 1 46 10.1186/s13148-020-0820-0 32171335
140 Dendrou C.A. Petersen J. Rossjohn J. Fugger L. HLA variation and disease. Nat. Rev. Immunol. 2018 18 5 325 339 10.1038/nri.2017.143 29292391
141 Shatz C.J. MHC class I: An unexpected role in neuronal plasticity. Neuron 2009 64 1 40 45 10.1016/j.neuron.2009.09.044 19840547
142 Sankar A. MacKenzie R.N. Foster J.A. Loss of class I MHC function alters behavior and stress reactivity. J. Neuroimmunol. 2012 244 1-2 8 15 10.1016/j.jneuroim.2011.12.025 22245287
143 Pasciuto E. Burton O.T. Roca C.P. Lagou V. Rajan W.D. Theys T. Mancuso R. Tito R.Y. Kouser L. Callaerts-Vegh Z. de la Fuente A.G. Prezzemolo T. Mascali L.G. Brajic A. Whyte C.E. Yshii L. Martinez-Muriana A. Naughton M. Young A. Moudra A. Lemaitre P. Poovathingal S. Raes J. De Strooper B. Fitzgerald D.C. Dooley J. Liston A. Microglia require CD4 T cells to complete the fetal-to-adult transition. Cell 2020 182 3 625 640.e24 10.1016/j.cell.2020.06.026 32702313
144 Schetters S.T.T. Gomez-Nicola D. Garcia-Vallejo J.J. Van Kooyk Y. Neuroinflammation: Microglia and T cells get ready to tango. Front. Immunol. 2018 8 1905 10.3389/fimmu.2017.01905 29422891
145 Byram S.C. Carson M.J. DeBoy C.A. Serpe C.J. Sanders V.M. Jones K.J. CD4-positive T cell-mediated neuroprotection requires dual compartment antigen presentation. J. Neurosci. 2004 24 18 4333 4339 10.1523/JNEUROSCI.5276-03.2004 15128847
146 Mittal K. Eremenko E. Berner O. Elyahu Y. Strominger I. Apelblat D. Nemirovsky A. Spiegel I. Monsonego A. CD4 T cells induce a subset of MHCII-expressing microglia that attenuates alzheimer pathology. iScience 2019 16 298 311 10.1016/j.isci.2019.05.039 31203186
147 Baker D.G. Nievergelt C.M. O’Connor D.T. Biomarkers of PTSD: Neuropeptides and immune signaling. Neuropharmacology 2012 62 2 663 673 10.1016/j.neuropharm.2011.02.027 21392516
148 Karanikas E. Daskalakis N.P. Agorastos A. Oxidative dysregulation in early life stress and posttraumatic stress disorder: A comprehensive review. Brain Sci. 2021 11 6 723 10.3390/brainsci11060723 34072322
149 Câmara A.B. Brandão I.A. Behavioral and neurochemical effects of nociceptin/orphanin FQ receptor activation in the social defeat protocol. Behav. Neurosci. 2022 137 1 52 66 10.1037/bne0000539 36326637
150 Behl T. Makkar R. Sehgal A. Singh S. Sharma N. Zengin G. Bungau S. Andronie-Cioara F.L. Munteanu M.A. Brisc M.C. Uivarosan D. Brisc C. Current trends in neurodegeneration: Cross talks between oxidative stress, cell death, and inflammation. Int. J. Mol. Sci. 2021 22 14 7432 10.3390/ijms22147432 34299052
151 Rana T. Behl T. Mehta V. Uddin M.S. Bungau S. Molecular insights into the therapeutic promise of targeting HMGB1 in depression. Pharmacol. Rep. 2021 73 1 31 42 10.1007/s43440-020-00163-6 33015736
152 Dantzer R. Kelley K.W. Twenty years of research on cytokine-induced sickness behavior. Brain Behav. Immun. 2007 21 2 153 160 10.1016/j.bbi.2006.09.006 17088043
153 Dooley L.N. Kuhlman K.R. Robles T.F. Eisenberger N.I. Craske M.G. Bower J.E. The role of inflammation in core features of depression: Insights from paradigms using exogenously-induced inflammation. Neurosci. Biobehav. Rev. 2018 94 219 237 10.1016/j.neubiorev.2018.09.006 30201219
154 Dunn A.J. Swiergiel A.H. Beaurepaire R. Cytokines as mediators of depression: What can we learn from animal studies? Neurosci. Biobehav. Rev. 2005 29 4-5 891 909 10.1016/j.neubiorev.2005.03.023 15885777
155 Raison C.L. Rutherford R.E. Woolwine B.J. Shuo C. Schettler P. Drake D.F. Haroon E. Miller A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013 70 1 31 41 10.1001/2013.jamapsychiatry.4 22945416
156 McIntyre R.S. Subramaniapillai M. Lee Y. Pan Z. Carmona N.E. Shekotikhina M. Rosenblat J.D. Brietzke E. Soczynska J.K. Cosgrove V.E. Miller S. Fischer E.G. Kramer N.E. Dunlap K. Suppes T. Mansur R.B. Efficacy of adjunctive infliximab vs. placebo in the treatment of adults with bipolar I/II depression. JAMA Psychiatry 2019 76 8 783 790 10.1001/jamapsychiatry.2019.0779 31066887
157 Knight J.M. Costanzo E.S. Singh S. Yin Z. Szabo A. Pawar D.S. Hillard C.J. Rizzo J.D. D’Souza A. Pasquini M. Coe C.L. Irwin M.R. Raison C.L. Drobyski W.R. The IL-6 antagonist tocilizumab is associated with worse depression and related symptoms in the medically ill. Transl. Psychiatry 2021 11 1 58 10.1038/s41398-020-01164-y 33462203
158 Husain M.I. Chaudhry I.B. Khoso A.B. Husain M.O. Hodsoll J. Ansari M.A. Naqvi H.A. Minhas F.A. Carvalho A.F. Meyer J.H. Deakin B. Mulsant B.H. Husain N. Young A.H. Minocycline and celecoxib as adjunctive treatments for bipolar depression: A multicentre, factorial design randomised controlled trial. Lancet Psychiatry 2020 7 6 515 527 10.1016/S2215-0366(20)30138-3 32445690
159 Berk M. Agustini B. Woods R.L. Nelson M.R. Shah R.C. Reid C.M. Storey E. Fitzgerald S.M. Lockery J.E. Wolfe R. Mohebbi M. Dodd S. Murray A.M. Stocks N. Fitzgerald P.B. Mazza C. McNeil J.J. Effects of aspirin on the long-term management of depression in older people: A double-blind randomised placebo-controlled trial. Mol. Psychiatry 2021 26 9 5161 5170 10.1038/s41380-021-01020-5 33504953
160 Berk M. Mohebbi M. Dean O.M. Cotton S.M. Chanen A.M. Dodd S. Ratheesh A. Amminger G.P. Phelan M. Weller A. Mackinnon A. Giorlando F. Baird S. Incerti L. Brodie R.E. Ferguson N.O. Rice S. Schäfer M.R. Mullen E. Hetrick S. Kerr M. Harrigan S.M. Quinn A.L. Mazza C. McGorry P. Davey C.G. Youth depression alleviation with anti-inflammatory agents (YoDA-A): A randomised clinical trial of rosuvastatin and aspirin. BMC Med. 2020 18 1 16 10.1186/s12916-019-1475-6 31948461
161 Verbitsky A. Dopfel D. Zhang N. Rodent models of post-traumatic stress disorder: Behavioral assessment. Transl. Psychiatry 2020 10 1 132 10.1038/s41398-020-0806-x 32376819
162 Johnson J.D. Barnard D.F. Kulp A.C. Mehta D.M. Neuroendocrine regulation of brain cytokines after psychological stress. J. Endocr. Soc. 2019 3 7 1302 1320 10.1210/js.2019-00053 31259292
163 Goshen I. Kreisel T. Ben-Menachem-Zidon O. Licht T. Weidenfeld J. Ben-Hur T. Yirmiya R. Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol. Psychiatry 2008 13 7 717 728 10.1038/sj.mp.4002055 17700577
164 Koo J.W. Duman R.S. IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc. Natl. Acad. Sci. USA 2008 105 2 751 756 10.1073/pnas.0708092105 18178625
165 Muhie S. Gautam A. Chakraborty N. Hoke A. Meyerhoff J. Hammamieh R. Jett M. Molecular indicators of stress-induced neuroinflammation in a mouse model simulating features of post-traumatic stress disorder. Transl. Psychiatry 2017 7 5 e1135 10.1038/tp.2017.91 28534873
166 Kim J. Yoon S. Lee S. Hong H. Ha E. Joo Y. Lee E.H. Lyoo I.K. A double-hit of stress and low-grade inflammation on functional brain network mediates posttraumatic stress symptoms. Nat. Commun. 2020 11 1 1898 10.1038/s41467-020-15655-5 32313055
167 Ganguly P. Brenhouse H.C. Broken or maladaptive? Altered trajectories in neuroinflammation and behavior after early life adversity. Dev. Cogn. Neurosci. 2015 11 18 30 10.1016/j.dcn.2014.07.001 25081071
168 Ferle V. Repouskou A. Aspiotis G. Raftogianni A. Chrousos G. Stylianopoulou F. Stamatakis A. Synergistic effects of early life mild adversity and chronic social defeat on rat brain microglia and cytokines. Physiol. Behav. 2020 215 112791 10.1016/j.physbeh.2019.112791 31870943
169 Cai Z. Ye T. Xu X. Gao M. Zhang Y. Wang D. Gu Y. Zhu H. Tong L. Lu J. Chen Z. Huang C. Antidepressive properties of microglial stimulation in a mouse model of depression induced by chronic unpredictable stress. Prog. Neuropsychopharmacol. Biol. Psychiatry 2020 101 109931 10.1016/j.pnpbp.2020.109931 32201112
170 Rimmerman N. Verdiger H. Goldenberg H. Naggan L. Robinson E. Kozela E. Gelb S. Reshef R. Ryan K.M. Ayoun L. Refaeli R. Ashkenazi E. Schottlender N. Ben Hemo-Cohen L. Pienica C. Aharonian M. Dinur E. Lazar K. McLoughlin D.M. Zvi A.B. Yirmiya R. Microglia and their LAG3 checkpoint underlie the antidepressant and neurogenesis-enhancing effects of electroconvulsive stimulation. Mol. Psychiatry 2022 27 2 1120 1135 10.1038/s41380-021-01338-0 34650207
171 Yirmiya R. Rimmerman N. Reshef R. Depression as a microglial disease. Trends Neurosci. 2015 38 10 637 658 10.1016/j.tins.2015.08.001 26442697
172 DellaGioia N. Hannestad J. A critical review of human endotoxin administration as an experimental paradigm of depression. Neurosci. Biobehav. Rev. 2010 34 1 130 143 10.1016/j.neubiorev.2009.07.014 19666048
173 Bauer J. Hohagen F. Gimmel E. Bruns F. Lis S. Krieger S. Ambach W. Guthmann A. Grunze H. Fritsch-Montero R. Weissbach A. Ganter U. Frommberger U. Riemann D. Berger M. Induction of cytokine synthesis and fever suppresses REM sleep and improves mood in patients with major depression. Biol. Psychiatry 1995 38 9 611 621 10.1016/0006-3223(95)00374-X 8573663
174 Lu X. Liu H. Cai Z. Hu Z. Ye M. Gu Y. Wang Y. Wang D. Lu Q. Shen Z. Shen X. Huang C. ERK1/2-dependent BDNF synthesis and signaling is required for the antidepressant effect of microglia stimulation. Brain Behav. Immun. 2022 106 147 160 10.1016/j.bbi.2022.08.005 35995236
175 Frank M.G. Baratta M.V. Sprunger D.B. Watkins L.R. Maier S.F. Microglia serve as a neuroimmune substrate for stress-induced potentiation of CNS pro-inflammatory cytokine responses. Brain Behav. Immun. 2007 21 1 47 59 10.1016/j.bbi.2006.03.005 16647243
176 Gu Y. Ye T. Tan P. Tong L. Ji J. Gu Y. Shen Z. Shen X. Lu X. Huang C. Tolerance-inducing effect and properties of innate immune stimulation on chronic stress-induced behavioral abnormalities in mice. Brain Behav. Immun. 2021 91 451 471 10.1016/j.bbi.2020.11.002 33157258
177 Lu Q. Xiang H. Zhu H. Chen Y. Lu X. Huang C. Intranasal lipopolysaccharide administration prevents chronic stress-induced depression- and anxiety-like behaviors in mice. Neuropharmacology 2021 200 108816 10.1016/j.neuropharm.2021.108816 34599975
178 Shi R. Liu H. Tan P. Hu Z. Ma Y. Ye M. Gu Y. Wang Y. Ye T. Gu Y. Lu X. Huang C. Innate immune stimulation prevents the development of anxiety-like behaviors in chronically stressed mice. Neuropharmacology 2022 207 108950 10.1016/j.neuropharm.2022.108950 35074304
179 Wang Y. Hu Z. Liu H. Gu Y. Ye M. Lu Q. Lu X. Huang C. Adolescent microglia stimulation produces long-lasting protection against chronic stress-induced behavioral abnormalities in adult male mice. Brain Behav. Immun. 2022 105 44 66 10.1016/j.bbi.2022.06.015 35781008
180 Mondelli V. Vernon A.C. Turkheimer F. Dazzan P. Pariante C.M. Brain microglia in psychiatric disorders. Lancet Psychiatry 2017 4 7 563 572 10.1016/S2215-0366(17)30101-3 28454915
181 Baker D.G. Ekhator N.N. Kasckow J.W. Hill K.K. Zoumakis E. Dashevsky B.A. Chrousos G.P. Geracioti T.D. Jr Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. Neuroimmunomodulation 2001 9 4 209 217 10.1159/000049028 11847483
182 Bonne O. Gill J.M. Luckenbaugh D.A. Collins C. Owens M.J. Alesci S. Neumeister A. Yuan P. Kinkead B. Manji H.K. Charney D.S. Vythilingam M. Corticotropin-releasing factor, interleukin-6, brain-derived neurotrophic factor, insulin-like growth factor-1, and substance P in the cerebrospinal fluid of civilians with posttraumatic stress disorder before and after treatment with paroxetine. J. Clin. Psychiatry 2011 72 8 1124 1128 10.4088/JCP.09m05106blu 21208596
183 Agorastos A. Hauger R.L. Barkauskas D.A. Lerman I.R. Moeller-Bertram T. Snijders C. Haji U. Patel P.M. Geracioti T.D. Chrousos G.P. Baker D.G. Relations of combat stress and posttraumatic stress disorder to 24-h plasma and cerebrospinal fluid interleukin-6 levels and circadian rhythmicity. Psychoneuroendocrinology 2019 100 237 245 10.1016/j.psyneuen.2018.09.009 30390522
184 Lerman I. Davis B.A. Bertram T.M. Proudfoot J. Hauger R.L. Coe C.L. Patel P.M. Baker D.G. Posttraumatic stress disorder influences the nociceptive and intrathecal cytokine response to a painful stimulus in combat veterans. Psychoneuroendocrinology 2016 73 99 108 10.1016/j.psyneuen.2016.07.202 27490714
185 Morrison F.G. Miller M.W. Wolf E.J. Logue M.W. Maniates H. Kwasnik D. Cherry J.D. Svirsky S. Restaino A. Hildebrandt A. Aytan N. Stein T.D. Alvarez V.E. McKee A.C. Huber B.R. Reduced interleukin 1A gene expression in the dorsolateral prefrontal cortex of individuals with PTSD and depression. Neurosci. Lett. 2019 692 204 209 10.1016/j.neulet.2018.10.027 30366016
186 Bhatt S. Hillmer A.T. Girgenti M.J. Rusowicz A. Kapinos M. Nabulsi N. Huang Y. Matuskey D. Angarita G.A. Esterlis I. Davis M.T. Southwick S.M. Friedman M.J. Girgenti M.J. Friedman M.J. Duman R.S. Krystal J.H. Duman R.S. Carson R.E. Krystal J.H. Pietrzak R.H. Cosgrove K.P. PTSD is associated with neuroimmune suppression: Evidence from PET imaging and postmortem transcriptomic studies. Nat. Commun. 2020 11 1 2360 10.1038/s41467-020-15930-5 32398677
187 Jaffe A.E. Tao R. Page S.C. Maynard K.R. Pattie E.A. Nguyen C.V. Deep-Soboslay A. Bharadwaj R. Young K.A. Friedman M.J. Williamson D.E. Shin J.H. Hyde T.M. Martinowich K. Kleinman J.E. Decoding shared versus divergent transcriptomic signatures across cortico-amygdala circuitry in PTSD and depressive disorders. Am. J. Psychiatry 2022 179 9 673 686 10.1176/appi.ajp.21020162 35791611
188 Fenster R.J. Lebois L.A.M. Ressler K.J. Suh J. Brain circuit dysfunction in post-traumatic stress disorder: From mouse to man. Nat. Rev. Neurosci. 2018 19 9 535 551 10.1038/s41583-018-0039-7 30054570
189 Girgenti M.J. Wang J. Ji D. Cruz D.A. Stein M.B. Gelernter J. Young K.A. Huber B.R. Williamson D.E. Friedman M.J. Krystal J.H. Zhao H. Duman R.S. Transcriptomic organization of the human brain in post-traumatic stress disorder. Nat. Neurosci. 2021 24 1 24 33 10.1038/s41593-020-00748-7 33349712
190 Logue M.W. Zhou Z. Morrison F.G. Wolf E.J. Daskalakis N.P. Chatzinakos C. Georgiadis F. Labadorf A.T. Girgenti M.J. Young K.A. Williamson D.E. Zhao X. Grenier J.G. Huber B.R. Miller M.W. Gene expression in the dorsolateral and ventromedial prefrontal cortices implicates immune-related gene networks in PTSD. Neurobiol. Stress 2021 15 100398 10.1016/j.ynstr.2021.100398 34646915
191 Sandiego C.M. Gallezot J.D. Pittman B. Nabulsi N. Lim K. Lin S.F. Matuskey D. Lee J.Y. O’Connor K.C. Huang Y. Carson R.E. Hannestad J. Cosgrove K.P. Imaging robust microglial activation after lipopolysaccharide administration in humans with PET. Proc. Natl. Acad. Sci. USA 2015 112 40 12468 12473 10.1073/pnas.1511003112 26385967
192 Holmes S.E. Girgenti M.J. Davis M.T. Pietrzak R.H. DellaGioia N. Nabulsi N. Matuskey D. Southwick S. Duman R.S. Carson R.E. Krystal J.H. Esterlis I. Friedman M. Kowall N. Brady C. McKee A. Stein T. Huber B. Kaloupek D. Alvarez V. Benedek D. Ursano R. Williamson D. Cruz D. Young K. Duman R. Krystal J. Mash D. Hardegree M. Serlin G. Altered metabotropic glutamate receptor 5 markers in PTSD: In vivo and postmortem evidence. Proc. Natl. Acad. Sci. USA 2017 114 31 8390 8395 10.1073/pnas.1701749114 28716937
193 Byrnes K.R. Stoica B. Loane D.J. Riccio A. Davis M.I. Faden A.I. Metabotropic glutamate receptor 5 activation inhibits microglial associated inflammation and neurotoxicity. Glia 2009 57 5 550 560 10.1002/glia.20783 18816644
194 Gill T. Watling S.E. Richardson J.D. McCluskey T. Tong J. Meyer J.H. Warsh J. Jetly R. Hutchison M.G. Rhind S.G. Houle S. Vasdev N. Kish S.J. Boileau I. Imaging of astrocytes in posttraumatic stress disorder: A PET study with the monoamine oxidase B radioligand [11C]SL25.1188. Eur. Neuropsychopharmacol. 2022 54 54 61 10.1016/j.euroneuro.2021.10.006 34773851
195 Reid J.K. Kuipers H.F. She Doesn’t Even Go Here: The role of inflammatory astrocytes in CNS disorders. Front. Cell. Neurosci. 2021 15 704884 10.3389/fncel.2021.704884 34539348
196 Wingo T.S. Gerasimov E.S. Liu Y. Duong D.M. Vattathil S.M. Lori A. Gockley J. Breen M.S. Maihofer A.X. Nievergelt C.M. Koenen K.C. Levey D.F. Gelernter J. Stein M.B. Ressler K.J. Bennett D.A. Levey A.I. Seyfried N.T. Wingo A.P. Integrating human brain proteomes with genome-wide association data implicates novel proteins in post-traumatic stress disorder. Mol. Psychiatry 2022 27 7 3075 3084 10.1038/s41380-022-01544-4 35449297
197 Friend S.F. C-Reactive Protein: Marker of risk for post-traumatic stress disorder and its potential for a mechanistic role in trauma response and recovery. Eur. J. Neurosci. 2020 55 9 10 33131159
198 Richards D.M. Kyewski B. Feuerer M. Re-examining the nature and function of self-reactive T cells. Trends Immunol. 2016 37 2 114 125 10.1016/j.it.2015.12.005 26795134
199 Cohen I.R. Real and artificial immune systems: Computing the state of the body. Nat. Rev. Immunol. 2007 7 7 569 574 10.1038/nri2102 17558422
200 Norris G.T. Kipnis J. Immune cells and CNS physiology: Microglia and beyond. J. Exp. Med. 2019 216 1 60 70 10.1084/jem.20180199 30504438
201 Schwartz M. Abellanas M.A. Tsitsou-Kampeli A. Suzzi S. The brain-immune ecosystem: Implications for immunotherapy in defeating neurodegenerative diseases. Neuron 2022 110 21 3421 3424 10.1016/j.neuron.2022.09.007 36150394
202 Correale J. Fiol M. Villa A. Neuroprotective Effects of Inflammation in the Nervous System. NeuroImmune Biology. Elsevier 2008 403 431 10.1016/S1567-7443(07)10020-X
203 Hohlfeld R. Kerschensteiner M. Stadelmann C. Lassmann H. Wekerle H. The neuroprotective effect of inflammation: Implications for the therapy of multiple sclerosis. Neurol. Sci. 2006 27 S1 Suppl. 1 s1 s7 10.1007/s10072-006-0537-7 16708174
204 Popovich P.G. Longbrake E.E. Can the immune system be harnessed to repair the CNS? Nat. Rev. Neurosci. 2008 9 6 481 493 10.1038/nrn2398 18490917
205 Schwartz M. Baruch K. The resolution of neuroinflammation in neurodegeneration: Leukocyte recruitment via the choroid plexus. EMBO J. 2014 33 1 7 22 10.1002/embj.201386609 24357543
206 Kerschensteiner M. Gallmeier E. Behrens L. Leal V.V. Misgeld T. Klinkert W.E.F. Kolbeck R. Hoppe E. Oropeza-Wekerle R.L. Bartke I. Stadelmann C. Lassmann H. Wekerle H. Hohlfeld R. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. Med. 1999 189 5 865 870 10.1084/jem.189.5.865 10049950
207 Schulte-Herbrüggen O. Nassenstein C. Lommatzsch M. Quarcoo D. Renz H. Braun A. Tumor necrosis factor-α and interleukin-6 regulate secretion of brain-derived neurotrophic factor in human monocytes. J. Neuroimmunol. 2005 160 1-2 204 209 10.1016/j.jneuroim.2004.10.026 15710474
208 van Buel E.M. Patas K. Peters M. Bosker F.J. Eisel U.L.M. Klein H.C. Immune and neurotrophin stimulation by electroconvulsive therapy: is some inflammation needed after all? Transl. Psychiatry 2015 5 7 e609 10.1038/tp.2015.100 26218851
209 Raison C.L. Knight J.M. Pariante C. Interleukin (IL)-6: A good kid hanging out with bad friends (and why sauna is good for health). Brain Behav. Immun. 2018 73 1 2 10.1016/j.bbi.2018.06.008 29908964
210 Patas K. Penninx B.W.J.H. Bus B.A.A. Vogelzangs N. Molendijk M.L. Elzinga B.M. Bosker F.J. Oude Voshaar R.C. Association between serum brain-derived neurotrophic factor and plasma interleukin-6 in major depressive disorder with melancholic features. Brain Behav. Immun. 2014 36 71 79 10.1016/j.bbi.2013.10.007 24140302
211 Hunter C.A. Jones S.A. IL-6 as a keystone cytokine in health and disease. Nat. Immunol. 2015 16 5 448 457 10.1038/ni.3153 25898198
212 Papanicolaou D.A. Wilder R.L. Manolagas S.C. Chrousos G.P. The pathophysiologic roles of interleukin-6 in human disease. Ann. Intern. Med. 1998 128 2 127 137 10.7326/0003-4819-128-2-199801150-00009 9441573
213 Jenkins R.H. Hughes S.T.O. Figueras A.C. Jones S.A. Unravelling the broader complexity of IL-6 involvement in health and disease. Cytokine 2021 148 155684 10.1016/j.cyto.2021.155684 34411990
214 Spooren A. Kolmus K. Laureys G. Clinckers R. De Keyser J. Haegeman G. Gerlo S. Interleukin-6, a mental cytokine. Brain Res. Brain Res. Rev. 2011 67 1-2 157 183 10.1016/j.brainresrev.2011.01.002 21238488
215 Rohleder N. Aringer M. Boentert M. Role of interleukin-6 in stress, sleep, and fatigue. Ann. N. Y. Acad. Sci. 2012 1261 1 88 96 10.1111/j.1749-6632.2012.06634.x 22823398
216 O’Donovan A. Chao L.L. Paulson J. Samuelson K.W. Shigenaga J.K. Grunfeld C. Weiner M.W. Neylan T.C. Altered inflammatory activity associated with reduced hippocampal volume and more severe posttraumatic stress symptoms in Gulf War veterans. Psychoneuroendocrinology 2015 51 557 566 10.1016/j.psyneuen.2014.11.010 25465168
217 Bruenig D. Mehta D. Morris C.P. Lawford B. Harvey W. McD Young R. Voisey J. Correlation between interferon γ and interleukin 6 with PTSD and resilience. Psychiatry Res. 2018 260 193 198 10.1016/j.psychres.2017.11.069 29202383
218 Mac Giollabhui N. Foster S. Lowry C.A. Mischoulon D. Raison C.L. Nyer M. Interleukin-6 receptor antagonists in immunopsychiatry: Can they lead to increased interleukin-6 in the central nervous system (CNS) and worsening psychiatric symptoms? Brain Behav. Immun. 2022 103 202 204 10.1016/j.bbi.2022.04.009 35452794
219 Mullard A. New plaque psoriasis approval carries suicide warning. Nat. Rev. Drug Discov. 2017 16 3 155 10.1038/nrd.2017.44 28248935
220 Minnema L.A. Giezen T.J. Souverein P.C. Egberts T.C.G. Leufkens H.G.M. Gardarsdottir H. Exploring the association between monoclonal antibodies and depression and suicidal ideation and behavior: A vigibase study. Drug Saf. 2019 42 7 887 895 10.1007/s40264-018-00789-9 30617497
221 Hunt D. Inflammation, monoclonal antibodies and depression: Joining the dots. Drug Saf. 2019 42 7 811 812 10.1007/s40264-019-00819-0 31069702
222 Ottum P.A. Arellano G. Reyes L.I. Iruretagoyena M. Naves R. Opposing roles of interferon-gamma on cells of the central nervous system in autoimmune neuroinflammation. Front. Immunol. 2015 6 539 10.3389/fimmu.2015.00539 26579119
223 Probert L. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. Neuroscience 2015 302 2 22 10.1016/j.neuroscience.2015.06.038 26117714
224 Zhang L. Hu X.Z. Li X. Chen Z. Benedek D.M. Fullerton C.S. Wynn G. Naifeh J.A. Wu H. Benfer N. Ng T.H.H. Aliaga P. Dinh H. Kao T-C. Ursano R.J. Potential chemokine biomarkers associated with PTSD onset, risk and resilience as well as stress responses in US military service members. Transl. Psychiatry 2020 10 1 31 10.1038/s41398-020-0693-1 32066664
225 Winter A.N. Subbarayan M.S. Grimmig B. Weesner J.A. Moss L. Peters M. Weeber E. Nash K. Bickford P.C. Two forms of CX3CL1 display differential activity and rescue cognitive deficits in CX3CL1 knockout mice. J. Neuroinflammation 2020 17 1 157 10.1186/s12974-020-01828-y 32410624
226 Heim C. Deficiency of inflammatory response to acute trauma exposure as a neuroimmune mechanism driving the development of chronic PTSD: Another paradigmatic shift for the conceptualization of stress-related disorders? Am. J. Psychiatry 2020 177 1 10 13 10.1176/appi.ajp.2019.19111189 31892300
227 Rohleder N. Karl A. Role of endocrine and inflammatory alterations in comorbid somatic diseases of post-traumatic stress disorder. Minerva Endocrinol. 2006 31 4 273 288 17213794
228 Segman R.H. Stein M.B. C-reactive protein: A stress diathesis marker at the crossroads of maladaptive behavioral and cardiometabolic sequelae. Am. J. Psychiatry 2015 172 4 307 309 10.1176/appi.ajp.2015.15010063 25827026
229 Agorastos A. Linthorst A.C.E. Potential pleiotropic beneficial effects of adjuvant melatonergic treatment in posttraumatic stress disorder. J. Pineal Res. 2016 61 1 3 26 10.1111/jpi.12330 27061919
230 Behl T. Kaur D. Sehgal A. Singla R.K. Makeen H.A. Albratty M. Alhazmi H.A. Meraya A.M. Bungau S. Therapeutic insights elaborating the potential of retinoids in Alzheimer’s disease. Front. Pharmacol. 2022 13 976799 10.3389/fphar.2022.976799 36091826
231 Colaço H.G. Moita L.F. Initiation of innate immune responses by surveillance of homeostasis perturbations. FEBS J. 2016 283 13 2448 2457 10.1111/febs.13730 27037950
232 Deri Y. Clouston S.A.P. DeLorenzo C. Gardus J.D. III Bartlett E.A. Santiago-Michels S. Bangiyev L. Kreisl W.C. Kotov R. Huang C. Slifstein M. Parsey R.V. Luft B.J. Neuroinflammation in World Trade Center responders at midlife: A pilot study using [18F]-FEPPA PET imaging Brain, Behavior, & Immunity - Health 2021 16 100287 10.1016/j.bbih.2021.100287 34589784
233 Toczek J. Hillmer A.T. Han J. Liu C. Peters D. Emami H. Wu J. Esterlis I. Cosgrove K.P. Sadeghi M.M. FDG PET imaging of vascular inflammation in post-traumatic stress disorder: A pilot case-control study. J. Nucl. Cardiol. 2021 28 2 688 694 10.1007/s12350-019-01724-w 31073848
